<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:tgtx="http://www.tgtherapeutics.com/20250630"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tgtx-20250630.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2025-08-05</instant>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tgtx:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tgtx:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ProductOrServiceAxis-LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tgtx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ProductOrServiceAxis-LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tgtx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ProductOrServiceAxis-LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tgtx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_ProductOrServiceAxis-LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tgtx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tgtx:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-LongTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tgtx:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_InvestmentTypeAxis-ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_TypeOfArrangementAxis-BriumviUblituximabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:BriumviUblituximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-BriumviUblituximabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:BriumviUblituximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:PrecisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-07</startDate>
            <endDate>2024-01-07</endDate>
        </period>
    </context>
    <context id="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:PrecisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-07</instant>
        </period>
    </context>
    <context id="d_2024-01-07_2024-01-07_RangeAxis-MaximumMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-07</startDate>
            <endDate>2024-01-07</endDate>
        </period>
    </context>
    <context id="i_2024-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-07</instant>
        </period>
    </context>
    <context id="d_2024-02-01_2024-02-28_LegalEntityAxis-PrecisionBiosciencesIncMember_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">tgtx:ReverseStockSplitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <context id="d_2025-01-07_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="i_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="i_2025-06-30_TypeOfArrangementAxis-PrecisionLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:PrecisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2010-03-01_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-03-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="i_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-03-31</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2022-09-02_SubsidiarySaleOfStockAxis-The2022AtmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tgtx:The2022AtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-02</instant>
        </period>
    </context>
    <context id="i_2024-08-02_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2012IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2012IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-The2012IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2012IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-11_PlanNameAxis-The2022IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2022IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-11</instant>
        </period>
    </context>
    <context id="i_2025-06-12_PlanNameAxis-The2022IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2022IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-12</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2022IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2022IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_PlanNameAxis-The2022IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:The2022IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-MilestoneBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tgtx:MilestoneBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-MarketbasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tgtx:MarketbasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AwardTypeAxis-MarketbasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tgtx:MarketbasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockAmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tgtx:WarrantsToPurchaseCommonStockAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockFirstAmendmentLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tgtx:WarrantsToPurchaseCommonStockFirstAmendmentLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockFirstAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tgtx:WarrantsToPurchaseCommonStockFirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-FederalFundsEffectiveSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_DebtInstrumentAxis-InitialTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_DebtInstrumentAxis-InitialTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_DebtInstrumentAxis-InitialTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:TheFirstAmendmentTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:TheFirstAmendmentTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:TheFirstAmendmentTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tgtx:TheFirstAmendmentTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2014-10-01_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementWithFortressBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="i_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementWithFortressBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-31</instant>
        </period>
    </context>
    <context id="i_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-DepositForOfficeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementWithFortressBiotechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">tgtx:DepositForOfficeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-31</instant>
        </period>
    </context>
    <context id="i_2021-10-31_RelatedPartyTransactionAxis-OfficeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="d_2021-10-01_2021-10-31_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:TheNorthCarolinaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:TheNorthCarolinaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_RelatedPartyTransactionAxis-OfficeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-OfficeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-OfficeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2019-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:TheNorthCarolinaLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2012-01-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2012-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-01-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-LFBLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:LFBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2012-12-01_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="i_2012-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:SublicenseAgreementWithIldongPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="d_2023-07-28_2023-07-28_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="i_2023-07-28_ProductOrServiceAxis-ProductMember_TypeOfArrangementAxis-BriumviUblituximabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:BriumviUblituximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="i_2023-07-28_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:CommercializationAgreementWithNeuraxpharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2024-01-07_2024-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tgtx:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-07</startDate>
            <endDate>2024-01-07</endDate>
        </period>
    </context>
    <context id="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:StrategicPlatformLicenseAgreementWithMaxcyteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="i_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tgtx:StrategicPlatformLicenseAgreementWithMaxcyteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2025-01-01_2025-06-30"
      id="thunderdome-EntityCentralIndexKey">0001001316</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2025-01-01_2025-06-30"
      id="thunderdome-EntityRegistrantName">TG THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-06-30" id="ixv-10703">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-06-30" id="ixv-10704">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-06-30" id="ixv-10705">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-06-30" id="ixv-10706">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-06-30"
      id="c133178740"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-12-31"
      id="c133178741"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133175747"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133175749"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133175750"
      unitRef="Share">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133175751"
      unitRef="Share">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133175752"
      unitRef="Share">158786335</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133175753"
      unitRef="Share">156204159</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133175754"
      unitRef="Share">158025237</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133175755"
      unitRef="Share">155836256</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133175760"
      unitRef="Share">761098</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133175761"
      unitRef="Share">367903</us-gaap:TreasuryStockCommonShares>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2025-06-30_TypeOfArrangementAxis-BriumviUblituximabMember"
      decimals="-3"
      id="c133176509"
      unitRef="USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryWriteDown
      contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-BriumviUblituximabMember"
      decimals="-3"
      id="c133176510"
      unitRef="USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2010-03-01_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember"
      id="c133176563">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2021-10-31_RelatedPartyTransactionAxis-OfficeAgreementMember"
      id="c133176848">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i_2025-06-30_RangeAxis-MinimumMember_RelatedPartyTransactionAxis-OfficeAgreementMember"
      id="c133176854">P2Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i_2025-06-30_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-OfficeAgreementMember"
      id="c133176855">P6Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2025-06-30_RelatedPartyTransactionAxis-OfficeAgreementMember"
      id="c133176856">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2012-01-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      id="c133176916">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2012-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      id="c133176925">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <tgtx:LicenseRevenue
      contextRef="d_2024-04-01_2024-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="INF"
      id="c133176981"
      unitRef="USD">38000</tgtx:LicenseRevenue>
    <us-gaap:Revenues
      contextRef="d_2025-01-01_2025-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176982"
      unitRef="USD">1100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-01-01_2024-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176983"
      unitRef="USD">1700000</us-gaap:Revenues>
    <tgtx:TermAfterFirstCommercialSale
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      id="c133176967">P10Y</tgtx:TermAfterFirstCommercialSale>
    <tgtx:LicenseAgreementTerm
      contextRef="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      id="c133176975">P10Y</tgtx:LicenseAgreementTerm>
    <tgtx:LicenseAgreementTerm
      contextRef="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      id="c133176978">P10Y</tgtx:LicenseAgreementTerm>
    <tgtx:LicenseAgreementRenewalTerm
      contextRef="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      id="c133176979">P5Y</tgtx:LicenseAgreementRenewalTerm>
    <tgtx:LicenseAgreementWrittenNoticePeriod
      contextRef="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      id="c133176980">P90D</tgtx:LicenseAgreementWrittenNoticePeriod>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-04-01_2025-06-30" id="c133177029">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-04-01_2025-06-30" id="c133177035">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-04-01_2025-06-30" id="c133177036">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-04-01_2025-06-30" id="c133177037">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2025-01-01_2025-06-30" id="ixv-12185">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2025-01-01_2025-06-30" id="ixv-12186">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-06-30" id="ixv-12187">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-06-30" id="ixv-12188">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-06-30" id="ixv-12189">001-32639</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-06-30" id="ixv-12190">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2025-01-01_2025-06-30" id="ixv-12191">36-3898269</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-06-30" id="ixv-12192">3020 Carrington Mill Blvd, Suite 475</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-06-30" id="ixv-12193">Morrisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-06-30" id="ixv-12194">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-06-30" id="ixv-12195">27560</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-06-30" id="ixv-12196">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-06-30" id="ixv-12197">575-8489</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-06-30" id="ixv-12198">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-06-30" id="ixv-12199">TGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-06-30" id="ixv-12200">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-06-30" id="ixv-12201">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-06-30" id="ixv-12202">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-06-30" id="ixv-12203">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-06-30" id="ixv-12204">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-06-30" id="ixv-12205">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-06-30" id="ixv-12206">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2025-08-05"
      decimals="INF"
      id="ixv-12207"
      unitRef="Share">158665613</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175693"
      unitRef="USD">129126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175694"
      unitRef="USD">179894000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175695"
      unitRef="USD">122744000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175696"
      unitRef="USD">131106000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175697"
      unitRef="USD">231516000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175698"
      unitRef="USD">129185000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175699"
      unitRef="USD">155202000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175700"
      unitRef="USD">110458000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175701"
      unitRef="USD">25374000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175702"
      unitRef="USD">15716000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175703"
      unitRef="USD">663962000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175704"
      unitRef="USD">566359000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175705"
      unitRef="USD">1316000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175706"
      unitRef="USD">1298000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c133175707"
      unitRef="USD">28590000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175708"
      unitRef="USD">808000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175709"
      unitRef="USD">6718000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175710"
      unitRef="USD">7151000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175711"
      unitRef="USD">2027000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175712"
      unitRef="USD">2074000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175713"
      unitRef="USD">702613000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c133175714"
      unitRef="USD">577690000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175717"
      unitRef="USD">134021000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175718"
      unitRef="USD">58296000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175719"
      unitRef="USD">2256000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175720"
      unitRef="USD">4627000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175721"
      unitRef="USD">1091000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175722"
      unitRef="USD">1157000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175723"
      unitRef="USD">23911000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175724"
      unitRef="USD">11414000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c133175725"
      unitRef="USD">10610000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175726"
      unitRef="USD">15185000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175727"
      unitRef="USD">171889000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175728"
      unitRef="USD">90679000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175729"
      unitRef="USD">1667000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175730"
      unitRef="USD">12085000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175731"
      unitRef="USD">245037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175732"
      unitRef="USD">244429000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175733"
      unitRef="USD">7588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175734"
      unitRef="USD">8133000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175735"
      unitRef="USD">426181000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175736"
      unitRef="USD">355326000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175744"
      unitRef="USD">159000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175745"
      unitRef="USD">156000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175756"
      unitRef="USD">1794212000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175757"
      unitRef="USD">1760396000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175758"
      unitRef="USD">21992000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175759"
      unitRef="USD">8994000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175762"
      unitRef="USD">-1495947000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175763"
      unitRef="USD">-1529194000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175764"
      unitRef="USD">276432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133175765"
      unitRef="USD">222364000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133175766"
      unitRef="USD">702613000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c133175767"
      unitRef="USD">577690000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133175781"
      unitRef="USD">138843000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133175782"
      unitRef="USD">72596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133175783"
      unitRef="USD">258498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133175784"
      unitRef="USD">123084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c133175785"
      unitRef="USD">2305000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30_ProductOrServiceAxis-LicenseMember"
      decimals="-4"
      id="c133175786"
      unitRef="USD">870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c133175787"
      unitRef="USD">3506000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c133175788"
      unitRef="USD">13855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175789"
      unitRef="USD">141148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175790"
      unitRef="USD">73466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175791"
      unitRef="USD">262004000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175792"
      unitRef="USD">136939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175794"
      unitRef="USD">18938000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175795"
      unitRef="USD">8304000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175796"
      unitRef="USD">34479000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175797"
      unitRef="USD">13745000</us-gaap:CostOfGoodsAndServicesSold>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175799"
      unitRef="USD">4318000</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c133175800"
      unitRef="USD">2520000</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175801"
      unitRef="USD">7649000</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175802"
      unitRef="USD">4972000</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175803"
      unitRef="USD">27464000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175804"
      unitRef="USD">15036000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175805"
      unitRef="USD">70495000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175806"
      unitRef="USD">45306000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175807"
      unitRef="USD">31782000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175808"
      unitRef="USD">17556000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175809"
      unitRef="USD">78144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175810"
      unitRef="USD">50278000</us-gaap:ResearchAndDevelopmentExpense>
    <tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175812"
      unitRef="USD">12044000</tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175813"
      unitRef="USD">6962000</tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175814"
      unitRef="USD">23684000</tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175815"
      unitRef="USD">13848000</tgtx:NonCashCompensationSellingGeneralAndAdministrativeExpenses>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175816"
      unitRef="USD">43541000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175817"
      unitRef="USD">31828000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175818"
      unitRef="USD">82232000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175819"
      unitRef="USD">59522000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175820"
      unitRef="USD">55585000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c133175821"
      unitRef="USD">38790000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175822"
      unitRef="USD">105916000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c133175823"
      unitRef="USD">73370000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175824"
      unitRef="USD">106305000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c133175825"
      unitRef="USD">64650000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175826"
      unitRef="USD">218539000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175827"
      unitRef="USD">137393000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175828"
      unitRef="USD">34843000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175829"
      unitRef="USD">8816000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175830"
      unitRef="USD">43465000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175831"
      unitRef="USD">-454000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175833"
      unitRef="USD">6716000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175834"
      unitRef="USD">3977000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175835"
      unitRef="USD">13473000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175836"
      unitRef="USD">6265000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175837"
      unitRef="USD">2793000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175838"
      unitRef="USD">1712000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175839"
      unitRef="USD">6396000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175840"
      unitRef="USD">2592000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175841"
      unitRef="USD">-3923000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175842"
      unitRef="USD">-2265000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175843"
      unitRef="USD">-7077000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175844"
      unitRef="USD">-3673000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-4"
      id="c133175845"
      unitRef="USD">30920000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175846"
      unitRef="USD">6551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175847"
      unitRef="USD">36388000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175848"
      unitRef="USD">-4127000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175849"
      unitRef="USD">2733000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175850"
      unitRef="USD">-328000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175851"
      unitRef="USD">3141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175852"
      unitRef="USD">-299000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133175853"
      unitRef="USD">28187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175854"
      unitRef="USD">6879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133175855"
      unitRef="USD">33247000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133175856"
      unitRef="USD">-3828000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133175858"
      unitRef="USDPerShare">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133175859"
      unitRef="USDPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133175860"
      unitRef="USDPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133175861"
      unitRef="USDPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133175862"
      unitRef="USDPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133175863"
      unitRef="USDPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133175864"
      unitRef="USDPerShare">0.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133175865"
      unitRef="USDPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133175867"
      unitRef="Share">146739833</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133175868"
      unitRef="Share">144727482</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133175869"
      unitRef="Share">146708980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133175870"
      unitRef="Share">145464255</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133175871"
      unitRef="Share">162559404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133175872"
      unitRef="Share">159423571</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133175873"
      unitRef="Share">162528551</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133175874"
      unitRef="Share">145464255</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175896"
      unitRef="Share">151465598</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175897"
      unitRef="USD">151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175898"
      unitRef="USD">1713162000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175899"
      unitRef="Share">41309</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175900"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175901"
      unitRef="USD">-1552577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c133175902"
      unitRef="USD">160502000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175903"
      unitRef="Share">2500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c133175905"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-4"
      id="c133175909"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175910"
      unitRef="Share">3304468</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175911"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175912"
      unitRef="USD">-4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c133175916"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175917"
      unitRef="Share">165514</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175926"
      unitRef="USD">10304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c133175930"
      unitRef="USD">10304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175936"
      unitRef="USD">-10707000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c133175937"
      unitRef="USD">-10707000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175938"
      unitRef="Share">154607052</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175939"
      unitRef="USD">155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175940"
      unitRef="USD">1723472000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175941"
      unitRef="Share">41309</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175942"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175943"
      unitRef="USD">-1563284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c133175944"
      unitRef="USD">160109000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175945"
      unitRef="Share">27250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175947"
      unitRef="USD">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175948"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175949"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175950"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175951"
      unitRef="USD">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175952"
      unitRef="Share">332138</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175954"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175955"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175956"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175957"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175958"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175959"
      unitRef="Share">92593</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175962"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175967"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175968"
      unitRef="USD">10445000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175970"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175971"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175972"
      unitRef="USD">10445000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175974"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175975"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175977"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175978"
      unitRef="USD">6879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133175979"
      unitRef="USD">6879000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133175980"
      unitRef="Share">154873847</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133175981"
      unitRef="USD">155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133175982"
      unitRef="USD">1734052000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133175983"
      unitRef="Share">41309</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133175984"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133175985"
      unitRef="USD">-1556405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c133175986"
      unitRef="USD">177568000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176008"
      unitRef="Share">156204159</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176009"
      unitRef="USD">156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176010"
      unitRef="USD">1760396000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176011"
      unitRef="Share">367903</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176012"
      unitRef="USD">-8994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176013"
      unitRef="USD">-1529194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176014"
      unitRef="USD">222364000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176015"
      unitRef="Share">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c133176017"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176018"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176019"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176020"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c133176021"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176022"
      unitRef="Share">2547179</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176023"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176024"
      unitRef="USD">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176025"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176026"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176027"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c133176028"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176029"
      unitRef="Share">20052</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176032"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176036"
      unitRef="Share">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176037"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176038"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176039"
      unitRef="Share">199695</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176040"
      unitRef="USD">6123000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176041"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c133176042"
      unitRef="USD">6123000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176044"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176045"
      unitRef="USD">15967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176047"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176048"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-3"
      id="c133176049"
      unitRef="USD">15967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176054"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-4"
      id="c133176055"
      unitRef="USD">5060000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-03-31"
      decimals="-4"
      id="c133176056"
      unitRef="USD">5060000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176057"
      unitRef="Share">158736286</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176058"
      unitRef="USD">159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176059"
      unitRef="USD">1776381000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176060"
      unitRef="Share">567598</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176061"
      unitRef="USD">-15117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176062"
      unitRef="USD">-1524134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c133176063"
      unitRef="USD">237289000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176064"
      unitRef="Share">46650</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176066"
      unitRef="USD">432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176067"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176068"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176069"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176070"
      unitRef="USD">432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176071"
      unitRef="Share">176467</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176074"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176075"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176076"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176077"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176078"
      unitRef="Share">173068</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176081"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      id="c133176085"
      unitRef="Share"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176086"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176087"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176088"
      unitRef="Share">193500</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176089"
      unitRef="USD">6875000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176090"
      unitRef="USD">-0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176091"
      unitRef="USD">6875000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176093"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176094"
      unitRef="USD">17399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176096"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176097"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176098"
      unitRef="USD">17399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176100"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      id="c133176101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176103"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176104"
      unitRef="USD">28187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176105"
      unitRef="USD">28187000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c133176106"
      unitRef="Share">158786335</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c133176107"
      unitRef="USD">159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133176108"
      unitRef="USD">1794212000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="INF"
      id="c133176109"
      unitRef="Share">761098</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-TreasuryStockCommonMember"
      decimals="-3"
      id="c133176110"
      unitRef="USD">-21992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c133176111"
      unitRef="USD">-1495947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176112"
      unitRef="USD">276432000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176120"
      unitRef="USD">33247000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176121"
      unitRef="USD">-3828000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176123"
      unitRef="USD">31333000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c133176124"
      unitRef="USD">18820000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176125"
      unitRef="USD">21000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176126"
      unitRef="USD">48000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176127"
      unitRef="USD">2619000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c133176128"
      unitRef="USD">3470000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176129"
      unitRef="USD">608000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176130"
      unitRef="USD">1278000</us-gaap:AmortizationOfFinancingCosts>
    <tgtx:AmortizationOfLeaseholdInterest
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176131"
      unitRef="USD">94000</tgtx:AmortizationOfLeaseholdInterest>
    <tgtx:AmortizationOfLeaseholdInterest
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176132"
      unitRef="USD">106000</tgtx:AmortizationOfLeaseholdInterest>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176133"
      unitRef="USD">885000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176134"
      unitRef="USD">905000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176135"
      unitRef="USD">-285000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176136"
      unitRef="USD">-178000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <tgtx:ChangeInFairValueOfNotesPayable
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176137"
      unitRef="USD">-149000</tgtx:ChangeInFairValueOfNotesPayable>
    <tgtx:ChangeInFairValueOfNotesPayable
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176138"
      unitRef="USD">-24000</tgtx:ChangeInFairValueOfNotesPayable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176140"
      unitRef="USD">42710000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176141"
      unitRef="USD">39491000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176142"
      unitRef="USD">9887000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c133176143"
      unitRef="USD">-2540000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176144"
      unitRef="USD">102331000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176145"
      unitRef="USD">32515000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176146"
      unitRef="USD">71150000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176147"
      unitRef="USD">49181000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176148"
      unitRef="USD">-1061000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176149"
      unitRef="USD">-1193000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176150"
      unitRef="USD">-2370000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176151"
      unitRef="USD">3646000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176152"
      unitRef="USD">1927000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c133176153"
      unitRef="USD">1100000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176154"
      unitRef="USD">-21279000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176155"
      unitRef="USD">-2671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176157"
      unitRef="USD">129750000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c133176158"
      unitRef="USD">144900000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176159"
      unitRef="USD">145359000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176160"
      unitRef="USD">151265000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176161"
      unitRef="USD">1250000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176162"
      unitRef="USD">1125000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176163"
      unitRef="USD">67000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176164"
      unitRef="USD">-0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176165"
      unitRef="USD">-16926000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c133176166"
      unitRef="USD">-7490000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176168"
      unitRef="USD">453000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176169"
      unitRef="USD">145000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176170"
      unitRef="USD">12998000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176171"
      unitRef="USD">-0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176172"
      unitRef="USD">-12545000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176173"
      unitRef="USD">145000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176174"
      unitRef="USD">-50750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176175"
      unitRef="USD">-10016000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176176"
      unitRef="USD">181192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c133176177"
      unitRef="USD">94218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176178"
      unitRef="USD">130442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c133176179"
      unitRef="USD">84202000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176181"
      unitRef="USD">129126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c133176182"
      unitRef="USD">82910000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176183"
      unitRef="USD">1316000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c133176184"
      unitRef="USD">1292000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176185"
      unitRef="USD">130442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c133176186"
      unitRef="USD">84202000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-4"
      id="c133176188"
      unitRef="USD">12240000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176189"
      unitRef="USD">4936000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176190"
      unitRef="USD">5077000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176191"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985495">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="notes" title="notes"&gt;&lt;/a&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt; - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Description of Business&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;TG Therapeutics&#x202f;is a fully-integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the FDA&#x202f;for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, as well as approval by the European Commission (EC),&#160;the Medicines and Healthcare Products Regulatory Agency (MHRA), Swissmedic, and Australia&#x2019;s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP), for interim financial information and with the instructions to Quarterly Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X&lt;/em&gt; of the Exchange Act. Accordingly, they &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the&#160;year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;. The accompanying condensed balance sheet as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt; has been derived from these statements. The results of operations for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for the entire fiscal&#160;year or any other interim period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;While we recently began generating net income, we have incurred significant operating losses since our inception. BRIUMVI &lt;em style="font: inherit;"&gt;first&lt;/em&gt; became commercially available in the United States in &lt;em style="font: inherit;"&gt; January &lt;/em&gt;of &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; and ex-US through our partner Neuraxpharm, in &lt;em style="font: inherit;"&gt; February 2024. &lt;/em&gt;Even with the commercialization of BRIUMVI and the possible future commercialization of our other drug candidates, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; realize continued profitability. During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;we generated $262.0&#160;million in revenue.&#160;Historically, substantially all our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations, including our commercialization activities to date. Our future operating results, profitability and other financial results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;fluctuate from period to period, and we will need to generate significant revenues to maintain profitability and/or positive cash flow on a sustained basis. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we have an accumulated deficit of approximately&#160;$1.5&#160;billion.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we had&#160;$278.9&#160;million in cash and cash equivalents, and&#160;investment securities. We anticipate that our cash, cash equivalents, and investment securities, combined with projected future revenues will provide sufficient liquidity for more than a &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period from the date of filing this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q. The actual amount of cash that we will need to operate is subject to many factors, including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, our commercialization efforts for BRIUMVI and the timing, design and conduct of clinical trials for our drug candidates as well as the costs associated with licensing or otherwise acquiring new product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be dependent upon significant future financing to provide the cash necessary to execute our ongoing and future operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Our common stock is quoted on the Nasdaq Capital Market and trades under the symbol &#x201c;TGTX.&#x201d;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Our significant accounting policies are described in Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Organization and Summary of Significant Accounting Policies to the audited consolidated financial statements included in our Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, except as updated herein or as it relates to revenue recognition, accounts receivable, inventory, cost of revenue, equity securities, and the adoption of new accounting standards during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;. Management does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe that any recently issued, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures ("ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09"&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; is effective for annual reporting periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is currently evaluating the impact of adopting this new accounting guidance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Pursuant to Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To achieve this core principle, Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; includes provisions within a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product Revenue, Net:&lt;/span&gt;&#160;The Company recognizes product revenues, net of variable consideration related to certain allowances and accruals, when the customer takes control of the product, which is typically upon delivery to the customer. Product revenue is recorded at the net sales price, or transaction price. The Company records product revenue reserves, which are classified as a reduction in product revenues, to account for the components of variable consideration. Variable consideration includes the following components, which are described below: chargebacks, government rebates, commercial payer rebates, trade discounts and allowances, product returns, and co-payment assistance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is expected to be settled with a credit against the Company&#x2019;s customer account) or a liability (if the amount is expected to be settled with a cash payment). The Company&#x2019;s estimates of reserves established for variable consideration are calculated based upon a consistent application of the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. These estimates reflect the Company's current contractual requirements,&#160;customer channel mix, changes to product price, government pricing calculations and industry data.&#160;The amount of variable consideration that is included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to constraint and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Actual amounts of consideration received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ultimately differ from the Company&#x2019;s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Chargebacks&lt;/span&gt;: Chargebacks for discounts represent the Company&#x2019;s estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers and government agencies at prices lower than the list prices charged to the customers who directly purchase the product from the Company. The customers charge the Company for the difference between what the customers pay the Company for the product and the customers&#x2019; ultimate contractually committed or government required lower selling price to the qualified healthcare providers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Government Rebates&lt;/span&gt;: Government rebates consist of Medicare, Tricare, and Medicaid rebates. These reserves are recorded in the same period the related revenue is recognized. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom it will owe a rebate under the Medicare Part D program.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Commercial Payer Rebates&lt;/span&gt;: The Company contracts with various private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of our product and contracted formulary status. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Trade Discounts and Allowances&lt;/span&gt;: The Company provides its customers with discounts that are explicitly stated in the applicable contracts and are recorded in the period the related product revenue is recognized. In addition, the Company also receives sales order management, inventory management, and data services from its customers in exchange for certain fees.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product Returns&lt;/span&gt;: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company. The Company estimates the amount of its product sales that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be returned by its customers and records this estimate in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Subject to certain limitations, the Company&#x2019;s return policy allows for eligible returns of commercial products sold&#160;for credit under the following circumstances:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; receipt of damaged product;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; shipment errors that were a result of an error by the Company;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; expired product that is returned during the period beginning &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months prior to the product&#x2019;s expiration and ending &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months after the expiration date;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; product subject to a recall; and&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; product that the Company, at its sole discretion, has specified can be returned for credit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;To date, the Company has experienced an immaterial amount of product returns related to sales of BRIUMVI.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Co-Payment Assistance Programs&lt;/span&gt;: Co-payment assistance is provided to qualified patients with commercial insurance, whereby the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide financial assistance to patients with prescription drug co-payments required by the patient's insurance provider. Reserves for co-payment assistance are recorded in the same period the related revenue is recognized.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company generates revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain products. Such agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include the transfer of intellectual property rights in the form of licenses. Payments made by the customer &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include non-refundable upfront fees, payments based upon the achievement of defined milestones, and royalties on sales of products.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Licenses of intellectual property&lt;/span&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the license as revenue upon transfer of control of the license. All other promised goods or services in the agreement are evaluated to determine if they are distinct. If they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Milestone payments&lt;/span&gt;: Contingent milestones at contract inception are estimated at the amount which is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable of a material reversal and included in the transaction price using the most likely amount method. Milestone payments that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the Company's control, such as regulatory approvals, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Company re-evaluates the probability of achieving development or sales-based milestone payments that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be subject to a material reversal and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Sales-based royalties:&lt;/span&gt; For arrangements that include sales-based royalties&#160;and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, revenue is recognized at the later of when the related sales occur or when the performance obligation to which some or all of the royalties have been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Optional Purchases:&lt;/span&gt; The Company&#x2019;s arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide the licensee the right to make optional purchases of the licensed product. These optional purchases are accounted for as separate contracts when the licensee determines that it will make such a purchase, unless the option conveys a material right. Optional purchases are recorded as product revenue, net.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Other Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Revenue is also generated from service-based fees recognized for providing regulatory support &amp;amp; development services to customers. Service fee revenue is recognized overtime as the services are transferred to the customer.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Deferred Product Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;When consideration is received, or such consideration is unconditionally due, from a customer prior to the Company completing its performance obligation to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. Deferred revenues expected to be recognized as revenue within the &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months following the balance sheet date are classified as current liabilities. Deferred revenues &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be recognized as revenue within the &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months following the balance sheet date are classified as long-term liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns and chargebacks. Our contracts with customers have standard payment terms. We analyze accounts that are past due for collectability, and regularly evaluate the creditworthiness of our customers so that we can properly assess and respond to changes in their credit profiles. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we determined an allowance for expected credit losses related to outstanding accounts receivable was currently &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required as they relate to large established credit worthy customers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Cost of Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cost of revenue consists primarily of royalties owed to our licensing partner for BRIUMVI sales, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party manufacturing costs, distribution&#160;and overhead.&#160;Cost of revenue &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. All manufacturing costs incurred to produce BRIUMVI prior to the approval of BRIUMVI by the FDA were expensed to research and development and therefore are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reflected in the cost of revenue. Therefore, a portion of costs incurred to produce&#160;BRIUMVI that was sold through the middle of the quarter ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;were previously&#160;expensed as research and development and are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reflected in our cost of revenue.&#160;Cost as it relates to providing regulatory support and development services to our ex-US commercialization partner Neuraxpharm is included in our cost of revenue.&lt;/p&gt;
   &lt;p style="text-indent: -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="text-indent: -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Inventories are stated at the lower of cost or estimated net realizable value with cost based on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-&lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method (FIFO). We will classify inventory costs as long-term, in other assets in our consolidated balance sheets, when we expect to utilize the inventory beyond our normal operating cycle.&#160;Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. Following regulatory approval, costs to manufacture those approved products will be capitalized. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in clinical trials.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Prior to the approval of BRIUMVI, all manufacturing and other potential costs related to the commercial launch of BRIUMVI were expensed to research and development expense in the period incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Equity Securities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Our&#160;equity securities consist of common stock of Precision BioSciences, Inc. (Precision). Equity securities are recognized at their fair value in accordance with ASC &lt;em style="font: inherit;"&gt;321,&lt;/em&gt; Investments &#x2013; Equity Securities. Forward contracts to purchase equity securities that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify as derivatives under ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; are accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;321.&lt;/em&gt; These forward contracts are recorded at fair value at the balance sheet date. See Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; - Fair Value Measures for further details.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Net Income (Loss) Per Common Share&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Basic net income (loss) per share of our common stock is calculated by dividing net income (loss) applicable to the common stock by the weighted-average number of shares of our common stock outstanding for the period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and restricted stock, which would result in the issuance of incremental shares of common stock. The impact of these items is anti-dilutive during periods of net loss. Therefore, as a result of the Company&#x2019;s net loss in the condensed consolidated statement of operations during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, basic and diluted net loss per share were the same&lt;i&gt;.&lt;/i&gt;&#160;For all other periods presented, the Company reported&#160;net income in the condensed consolidated statement of operations and as such presents the dilutive effect of potential common shares in the computation of basic and diluted earnings per share in the table below.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table summarizes our potentially dilutive securities at &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;11,270,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;9,872,652&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,362,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,667,279&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;165,214&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;312,272&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Shares issuable upon note conversion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,973&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,434&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,873,637&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The computation of basic and diluted EPS is as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands, except share and per share data)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,187&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,879&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,828&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,739,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;144,727,482&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,708,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive effect of potential common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,696,089&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding assuming dilution&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,559,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;159,423,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,528,551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating segments are defined as components of an enterprise that engage in business activities from which it&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;recognize revenues and incur expenses, and for which discrete financial information is available that is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) to allocate resources and assess performance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company operates in&#160;one&#160;reportable segment, B-cell mediated disease therapy, which includes all activities related to the development and commercialization of novel treatments, including BRIUMVI, to address unmet medical needs and improve the lives of patients. The determination of a single reportable segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s CODM, which is its chief executive officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&lt;/p&gt;


  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178742">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP), for interim financial information and with the instructions to Quarterly Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X&lt;/em&gt; of the Exchange Act. Accordingly, they &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the&#160;year ended &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;. The accompanying condensed balance sheet as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt; has been derived from these statements. The results of operations for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for the entire fiscal&#160;year or any other interim period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <tgtx:LiquidityAndCapitalResourcesPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178743">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;While we recently began generating net income, we have incurred significant operating losses since our inception. BRIUMVI &lt;em style="font: inherit;"&gt;first&lt;/em&gt; became commercially available in the United States in &lt;em style="font: inherit;"&gt; January &lt;/em&gt;of &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; and ex-US through our partner Neuraxpharm, in &lt;em style="font: inherit;"&gt; February 2024. &lt;/em&gt;Even with the commercialization of BRIUMVI and the possible future commercialization of our other drug candidates, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; realize continued profitability. During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;we generated $262.0&#160;million in revenue.&#160;Historically, substantially all our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations, including our commercialization activities to date. Our future operating results, profitability and other financial results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;fluctuate from period to period, and we will need to generate significant revenues to maintain profitability and/or positive cash flow on a sustained basis. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we have an accumulated deficit of approximately&#160;$1.5&#160;billion.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we had&#160;$278.9&#160;million in cash and cash equivalents, and&#160;investment securities. We anticipate that our cash, cash equivalents, and investment securities, combined with projected future revenues will provide sufficient liquidity for more than a &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period from the date of filing this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q. The actual amount of cash that we will need to operate is subject to many factors, including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, our commercialization efforts for BRIUMVI and the timing, design and conduct of clinical trials for our drug candidates as well as the costs associated with licensing or otherwise acquiring new product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be dependent upon significant future financing to provide the cash necessary to execute our ongoing and future operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Our common stock is quoted on the Nasdaq Capital Market and trades under the symbol &#x201c;TGTX.&#x201d;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   </tgtx:LiquidityAndCapitalResourcesPolicyPolicyTextBlock>
    <tgtx:LicenseAndCollaborationAgreementsOnetimeNonrefundablePayment
      contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-6"
      id="c133176231"
      unitRef="USD">262000000</tgtx:LicenseAndCollaborationAgreementsOnetimeNonrefundablePayment>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-8"
      id="c133176232"
      unitRef="USD">-1500000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c133176234"
      unitRef="USD">278900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178744">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures ("ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09"&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; is effective for annual reporting periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is currently evaluating the impact of adopting this new accounting guidance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178745">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Pursuant to Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To achieve this core principle, Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; includes provisions within a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product Revenue, Net:&lt;/span&gt;&#160;The Company recognizes product revenues, net of variable consideration related to certain allowances and accruals, when the customer takes control of the product, which is typically upon delivery to the customer. Product revenue is recorded at the net sales price, or transaction price. The Company records product revenue reserves, which are classified as a reduction in product revenues, to account for the components of variable consideration. Variable consideration includes the following components, which are described below: chargebacks, government rebates, commercial payer rebates, trade discounts and allowances, product returns, and co-payment assistance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is expected to be settled with a credit against the Company&#x2019;s customer account) or a liability (if the amount is expected to be settled with a cash payment). The Company&#x2019;s estimates of reserves established for variable consideration are calculated based upon a consistent application of the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. These estimates reflect the Company's current contractual requirements,&#160;customer channel mix, changes to product price, government pricing calculations and industry data.&#160;The amount of variable consideration that is included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to constraint and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Actual amounts of consideration received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ultimately differ from the Company&#x2019;s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Chargebacks&lt;/span&gt;: Chargebacks for discounts represent the Company&#x2019;s estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers and government agencies at prices lower than the list prices charged to the customers who directly purchase the product from the Company. The customers charge the Company for the difference between what the customers pay the Company for the product and the customers&#x2019; ultimate contractually committed or government required lower selling price to the qualified healthcare providers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Government Rebates&lt;/span&gt;: Government rebates consist of Medicare, Tricare, and Medicaid rebates. These reserves are recorded in the same period the related revenue is recognized. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom it will owe a rebate under the Medicare Part D program.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Commercial Payer Rebates&lt;/span&gt;: The Company contracts with various private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of our product and contracted formulary status. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Trade Discounts and Allowances&lt;/span&gt;: The Company provides its customers with discounts that are explicitly stated in the applicable contracts and are recorded in the period the related product revenue is recognized. In addition, the Company also receives sales order management, inventory management, and data services from its customers in exchange for certain fees.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product Returns&lt;/span&gt;: Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company. The Company estimates the amount of its product sales that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be returned by its customers and records this estimate in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Subject to certain limitations, the Company&#x2019;s return policy allows for eligible returns of commercial products sold&#160;for credit under the following circumstances:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; receipt of damaged product;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; shipment errors that were a result of an error by the Company;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; expired product that is returned during the period beginning &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months prior to the product&#x2019;s expiration and ending &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months after the expiration date;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; product subject to a recall; and&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 28pt;"&gt;&#x25cf; product that the Company, at its sole discretion, has specified can be returned for credit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;To date, the Company has experienced an immaterial amount of product returns related to sales of BRIUMVI.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Co-Payment Assistance Programs&lt;/span&gt;: Co-payment assistance is provided to qualified patients with commercial insurance, whereby the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide financial assistance to patients with prescription drug co-payments required by the patient's insurance provider. Reserves for co-payment assistance are recorded in the same period the related revenue is recognized.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company generates revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain products. Such agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include the transfer of intellectual property rights in the form of licenses. Payments made by the customer &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include non-refundable upfront fees, payments based upon the achievement of defined milestones, and royalties on sales of products.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Licenses of intellectual property&lt;/span&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the license as revenue upon transfer of control of the license. All other promised goods or services in the agreement are evaluated to determine if they are distinct. If they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Milestone payments&lt;/span&gt;: Contingent milestones at contract inception are estimated at the amount which is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable of a material reversal and included in the transaction price using the most likely amount method. Milestone payments that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the Company's control, such as regulatory approvals, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Company re-evaluates the probability of achieving development or sales-based milestone payments that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be subject to a material reversal and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Sales-based royalties:&lt;/span&gt; For arrangements that include sales-based royalties&#160;and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, revenue is recognized at the later of when the related sales occur or when the performance obligation to which some or all of the royalties have been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;Optional Purchases:&lt;/span&gt; The Company&#x2019;s arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;provide the licensee the right to make optional purchases of the licensed product. These optional purchases are accounted for as separate contracts when the licensee determines that it will make such a purchase, unless the option conveys a material right. Optional purchases are recorded as product revenue, net.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Other Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Revenue is also generated from service-based fees recognized for providing regulatory support &amp;amp; development services to customers. Service fee revenue is recognized overtime as the services are transferred to the customer.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Deferred Product Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;When consideration is received, or such consideration is unconditionally due, from a customer prior to the Company completing its performance obligation to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. Deferred revenues expected to be recognized as revenue within the &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months following the balance sheet date are classified as current liabilities. Deferred revenues &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be recognized as revenue within the &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months following the balance sheet date are classified as long-term liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178746">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns and chargebacks. Our contracts with customers have standard payment terms. We analyze accounts that are past due for collectability, and regularly evaluate the creditworthiness of our customers so that we can properly assess and respond to changes in their credit profiles. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we determined an allowance for expected credit losses related to outstanding accounts receivable was currently &lt;em style="font: inherit;"&gt;not&lt;/em&gt; required as they relate to large established credit worthy customers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178747">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Cost of Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Cost of revenue consists primarily of royalties owed to our licensing partner for BRIUMVI sales, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party manufacturing costs, distribution&#160;and overhead.&#160;Cost of revenue &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. All manufacturing costs incurred to produce BRIUMVI prior to the approval of BRIUMVI by the FDA were expensed to research and development and therefore are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reflected in the cost of revenue. Therefore, a portion of costs incurred to produce&#160;BRIUMVI that was sold through the middle of the quarter ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;were previously&#160;expensed as research and development and are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reflected in our cost of revenue.&#160;Cost as it relates to providing regulatory support and development services to our ex-US commercialization partner Neuraxpharm is included in our cost of revenue.&lt;/p&gt;
   &lt;p style="text-indent: -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178748">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Inventories are stated at the lower of cost or estimated net realizable value with cost based on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in-&lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method (FIFO). We will classify inventory costs as long-term, in other assets in our consolidated balance sheets, when we expect to utilize the inventory beyond our normal operating cycle.&#160;Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. Following regulatory approval, costs to manufacture those approved products will be capitalized. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in clinical trials.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Prior to the approval of BRIUMVI, all manufacturing and other potential costs related to the commercial launch of BRIUMVI were expensed to research and development expense in the period incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178749">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Equity Securities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Our&#160;equity securities consist of common stock of Precision BioSciences, Inc. (Precision). Equity securities are recognized at their fair value in accordance with ASC &lt;em style="font: inherit;"&gt;321,&lt;/em&gt; Investments &#x2013; Equity Securities. Forward contracts to purchase equity securities that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify as derivatives under ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; are accounted for in accordance with ASC &lt;em style="font: inherit;"&gt;321.&lt;/em&gt; These forward contracts are recorded at fair value at the balance sheet date. See Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; - Fair Value Measures for further details.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178750">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;Net Income (Loss) Per Common Share&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Basic net income (loss) per share of our common stock is calculated by dividing net income (loss) applicable to the common stock by the weighted-average number of shares of our common stock outstanding for the period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and restricted stock, which would result in the issuance of incremental shares of common stock. The impact of these items is anti-dilutive during periods of net loss. Therefore, as a result of the Company&#x2019;s net loss in the condensed consolidated statement of operations during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, basic and diluted net loss per share were the same&lt;i&gt;.&lt;/i&gt;&#160;For all other periods presented, the Company reported&#160;net income in the condensed consolidated statement of operations and as such presents the dilutive effect of potential common shares in the computation of basic and diluted earnings per share in the table below.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table summarizes our potentially dilutive securities at &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;11,270,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;9,872,652&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,362,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,667,279&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;165,214&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;312,272&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Shares issuable upon note conversion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,973&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,434&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,873,637&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The computation of basic and diluted EPS is as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands, except share and per share data)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,187&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,879&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,828&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,739,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;144,727,482&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,708,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive effect of potential common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,696,089&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding assuming dilution&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,559,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;159,423,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,528,551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985496">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Unvested restricted stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;11,270,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;9,872,652&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,362,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;4,667,279&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;165,214&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;312,272&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Shares issuable upon note conversion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,973&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,434&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,873,637&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockMember"
      decimals="INF"
      id="c133176308"
      unitRef="Share">11270068</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockMember"
      decimals="INF"
      id="c133176309"
      unitRef="Share">9872652</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c133176310"
      unitRef="Share">4362316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c133176311"
      unitRef="Share">4667279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c133176312"
      unitRef="Share">165214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c133176313"
      unitRef="Share">312272</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c133176314"
      unitRef="Share">21973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c133176315"
      unitRef="Share">21434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176316"
      unitRef="Share">15819571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176317"
      unitRef="Share">14873637</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985497">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands, except share and per share data)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,187&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,879&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,828&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,739,833&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;144,727,482&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,708,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive effect of potential common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,696,089&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,819,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average common shares outstanding assuming dilution&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,559,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;159,423,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,528,551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;145,464,255&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share - diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176330"
      unitRef="USD">28187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133176331"
      unitRef="USD">6879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176332"
      unitRef="USD">33247000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176333"
      unitRef="USD">-3828000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176334"
      unitRef="Share">146739833</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133176335"
      unitRef="Share">144727482</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176336"
      unitRef="Share">146708980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176337"
      unitRef="Share">145464255</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176338"
      unitRef="Share">15819571</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133176339"
      unitRef="Share">14696089</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176340"
      unitRef="Share">15819571</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176341"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176342"
      unitRef="Share">162559404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133176343"
      unitRef="Share">159423571</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176344"
      unitRef="Share">162528551</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176345"
      unitRef="Share">145464255</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176346"
      unitRef="USDPerShare">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133176347"
      unitRef="USDPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176348"
      unitRef="USDPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176349"
      unitRef="USDPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176350"
      unitRef="USDPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c133176351"
      unitRef="USDPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176352"
      unitRef="USDPerShare">0.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176353"
      unitRef="USDPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-06-30" id="c133178751">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operating segments are defined as components of an enterprise that engage in business activities from which it&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;recognize revenues and incur expenses, and for which discrete financial information is available that is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) to allocate resources and assess performance.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company operates in&#160;one&#160;reportable segment, B-cell mediated disease therapy, which includes all activities related to the development and commercialization of novel treatments, including BRIUMVI, to address unmet medical needs and improve the lives of patients. The determination of a single reportable segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s CODM, which is its chief executive officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176297"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985498">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;2&lt;/em&gt; - REVENUE&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As discussed in Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Organization and Summary of Significant Accounting Policies, revenues are recognized under guidance within ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total product revenue, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;138,843&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;72,596&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;258,498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;123,084&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;License, milestone, royalty and other revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;2,305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;3,506&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;13,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;141,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;73,466&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;136,939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Product Revenue, net&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;For&#160;the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, our only source of product revenue has been from U.S. sales of BRIUMVI, which we began shipping to our customers in &lt;em style="font: inherit;"&gt; January 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;gross-to-net accruals of approximately $16.1&#160;million and $33.3&#160;million are included on the condensed consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company primarily sells BRIUMVI through specialty distributors. The following table summarizes the customers that represent &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or greater of gross product revenue for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 1&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;41&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;38&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 2&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;25&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;33&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;29&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;32&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 3&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;17&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;16&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 4&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;12&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following table summarizes the customers with amounts due that represent &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or greater of the accounts receivable associated with the Company&#x2019;s product sales as of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 1&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 2&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 3&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 4&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;License, Milestone, Royalty and Other Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;License, milestone, royalty and other revenue consist of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm. Refer to Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; - License Agreements for a description of the Commercialization Agreement and for further information of the accounting in accordance with ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985499">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total product revenue, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;138,843&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;72,596&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;258,498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;123,084&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;License, milestone, royalty and other revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;2,305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;3,506&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;13,855&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;141,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;73,466&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;136,939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133176380"
      unitRef="USD">138843000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133176381"
      unitRef="USD">72596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133176382"
      unitRef="USD">258498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c133176383"
      unitRef="USD">123084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30_ProductOrServiceAxis-LicenseRevenueMember"
      decimals="-3"
      id="c133176384"
      unitRef="USD">2305000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30_ProductOrServiceAxis-LicenseRevenueMember"
      decimals="-4"
      id="c133176385"
      unitRef="USD">870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30_ProductOrServiceAxis-LicenseRevenueMember"
      decimals="-3"
      id="c133176386"
      unitRef="USD">3506000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30_ProductOrServiceAxis-LicenseRevenueMember"
      decimals="-3"
      id="c133176387"
      unitRef="USD">13855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176389"
      unitRef="USD">141148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133176391"
      unitRef="USD">73466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176393"
      unitRef="USD">262004000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176395"
      unitRef="USD">136939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tgtx:GrossNetAccruals
      contextRef="i_2025-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-5"
      id="c133176359"
      unitRef="USD">16100000</tgtx:GrossNetAccruals>
    <tgtx:GrossNetAccruals
      contextRef="i_2024-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-5"
      id="c133176360"
      unitRef="USD">33300000</tgtx:GrossNetAccruals>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="d_2025-01-01_2025-06-30"
      id="c6556EB2E-855A-44F5-9439-35F758C376AC">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 1&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;41&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;38&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 2&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;25&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;33&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;29&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;32&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 3&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;17&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;16&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 4&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;12&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 1&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 2&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 3&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Customer 4&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-04-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c133176405"
      unitRef="Pure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-04-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c133176406"
      unitRef="Pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c133176411"
      unitRef="Pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c133176413"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-04-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"
      decimals="2"
      id="c133176416"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-04-01_2024-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"
      decimals="2"
      id="c133176418"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="1"
      id="c133176429"
      unitRef="Pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember"
      decimals="2"
      id="c133176430"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c133176431"
      unitRef="Pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember"
      decimals="2"
      id="c133176432"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"
      decimals="2"
      id="c133176433"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerThreeMember"
      decimals="2"
      id="c133176434"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2025-01-01_2025-06-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerFourMember"
      decimals="2"
      id="c133176435"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerFourMember"
      decimals="2"
      id="c133176436"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985502">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt; - INVESTMENT SECURITIES&#160;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Our short-term and long-term investment securities&#160;as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt; are classified as held-to-maturity. Held-to-maturity investments are recorded at amortized cost.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following tables summarize our short-term and long-term investment securities at &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;cost, as&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;adjusted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;fair value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Short-term obligations of domestic governmental agencies (maturing between July 2025 and June 2026) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;122,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;122,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term obligations of domestic governmental agencies (maturing between July 2026 and May 2027) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26,990&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total short-term and long-term investment securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;149,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;57&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;149,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;cost, as&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;adjusted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;fair value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Short-term obligations of domestic governmental agencies (maturing between January 2025 and December 2025) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;131,106&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;131,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total short-term investment securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;131,106&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;131,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 36pt;"&gt;Included in long-term investments on the condensed consolidated balance sheet, are equity securities as a result of the Precision License Agreement. See Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; - Fair Value Measurements for a description of the Precision License Agreement and for further information on our equity investments.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="d_2025-01-01_2025-06-30"
      id="A4C2E925-8DCE-4165-BEBC-1A3124F0EF43">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;cost, as&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;adjusted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;fair value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Short-term obligations of domestic governmental agencies (maturing between July 2025 and June 2026) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;122,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;122,725&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Long-term obligations of domestic governmental agencies (maturing between July 2026 and May 2027) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26,990&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total short-term and long-term investment securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;149,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;57&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(25&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;149,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gross&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;cost, as&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;unrealized&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;adjusted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;holding losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;fair value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Short-term obligations of domestic governmental agencies (maturing between January 2025 and December 2025) (held-to-maturity)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;131,106&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;131,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total short-term investment securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;131,106&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;64&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;131,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176456"
      unitRef="USD">122744000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176457"
      unitRef="USD">5000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176458"
      unitRef="USD">24000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176459"
      unitRef="USD">122725000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-LongTermInvestmentsMember"
      decimals="-4"
      id="c133176464"
      unitRef="USD">26990000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-LongTermInvestmentsMember"
      decimals="-3"
      id="c133176465"
      unitRef="USD">52000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-LongTermInvestmentsMember"
      decimals="-3"
      id="c133176466"
      unitRef="USD">1000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2025-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-LongTermInvestmentsMember"
      decimals="-3"
      id="c133176467"
      unitRef="USD">27041000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176472"
      unitRef="USD">149734000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176473"
      unitRef="USD">57000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176474"
      unitRef="USD">25000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176475"
      unitRef="USD">149766000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176494"
      unitRef="USD">131106000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176495"
      unitRef="USD">64000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176496"
      unitRef="USD">-0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-4"
      id="c133176497"
      unitRef="USD">131170000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i_2024-12-31_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176500"
      unitRef="USD">131106000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i_2024-12-31_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176501"
      unitRef="USD">64000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i_2024-12-31_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-3"
      id="c133176502"
      unitRef="USD">-0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i_2024-12-31_InvestmentTypeAxis-ShortTermInvestmentsMember"
      decimals="-4"
      id="c133176503"
      unitRef="USD">131170000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985505">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;4&lt;/em&gt; - INVENTORY&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following table presents our inventory as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024 (&lt;/em&gt;in thousands):&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; border-collapse: collapse; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Raw Materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,119&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;28,151&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Work in Process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;129,239&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;68,369&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Finished Goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;21,844&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;13,938&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;155,202&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;110,458&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.&#160;Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 28pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;At &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, our inventory was solely related to BRIUMVI, which was approved by the FDA in &lt;em style="font: inherit;"&gt; December 2022, &lt;/em&gt;at which time we began to capitalize costs to manufacture BRIUMVI. Prior to the FDA approval of BRIUMVI, all costs related to the manufacturing of BRIUMVI and related material were charged to research and development expense in the period incurred.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The work in process materials consist primarily of bulk drug substance, which has a multi-year shelf life.&#160;When the bulk drug substance is manufactured into BRIUMVI finished goods, those finished goods have a shelf life of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years from the date of manufacture.&#160;Our expectation is to sell finished goods at least &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months prior to expiration. Due to our long manufacturing lead time, it was necessary to build&#160;inventory levels to&#160;support BRIUMVI forecasted sales, to ensure appropriate safety stock levels, and meet our commitment to supply BRIUMVI to Neuraxpharm related to the Commercialization Agreement. As a result of being in the early stages of the BRIUMVI product launch, the Company is continuing to evaluate the length of its operating cycle.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On a quarterly basis, the Company analyzes our inventory levels for excess quantities and obsolescence (expiration), taking into account factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life. At &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, we determined that a reserve related to BRIUMVI inventory for excess quantities and obsolescence is &lt;span style="-sec-ix-hidden:c133176509"&gt;not&lt;/span&gt; required. In addition, since FDA approval of BRIUMVI, the Company has &lt;span style="-sec-ix-hidden:c133176510"&gt;not&lt;/span&gt; recorded any inventory write downs.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The United States and other countries have recently imposed, and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;continue to impose, new tariffs. Tariffs are an inventoriable cost, and our sole supplier of bulk drug substance is located outside of the U.S. While the tariffs imposed to date have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; resulted in a material impact on our business and the results of operations, we continue to evaluate their impact on our business and results of operations.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985506">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; border-collapse: collapse; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30, 2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31, 2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Raw Materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,119&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;28,151&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Work in Process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;129,239&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;68,369&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Finished Goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;21,844&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;13,938&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Total Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;155,202&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;110,458&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176514"
      unitRef="USD">4119000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176515"
      unitRef="USD">28151000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176516"
      unitRef="USD">129239000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176517"
      unitRef="USD">68369000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcessNetOfReserves
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176518"
      unitRef="USD">21844000</us-gaap:InventoryFinishedGoodsAndWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcessNetOfReserves
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176519"
      unitRef="USD">13938000</us-gaap:InventoryFinishedGoodsAndWorkInProcessNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176520"
      unitRef="USD">155202000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176521"
      unitRef="USD">110458000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985507">
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;5&lt;/em&gt; - FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis in the condensed consolidated financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following &lt;em style="font: inherit;"&gt;three&lt;/em&gt; categories:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; quoted prices in active markets for identical assets and liabilities;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs other than Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; quoted prices that are directly or indirectly observable; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; unobservable inputs that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; corroborated by market data.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Equity Investments and Forward Contract Liabilities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2024, &lt;/em&gt;the Company and its wholly-owned subsidiary, TG Cell Therapy, Inc., (TG Cell) entered into a License Agreement (the Precision License Agreement) with Precision, pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision&#x2019;s allogeneic CAR T therapy, azer-cel,&#160;for the treatment of autoimmune and other non-oncology diseases and conditions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Upon execution of the Precision License Agreement, the Company made an upfront payment to Precision of $7.5 million, consisting of (i) $5.25 million in cash and (ii) $2.25 million (the Upfront Precision Stock Payment), as an equity investment, for the purchase of 2,920,816 shares of Precision&#x2019;s common stock at a price of $0.77 per share. The Company paid a premium for the shares which was recorded in research and development&#160;expense as part of the cost of the Precision License Agreement. Precision subsequently implemented a 30-to-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; reverse stock split in &lt;em style="font: inherit;"&gt; February 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; January 7, 2025, &lt;/em&gt;the Company made a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time payment to Precision equal to $2.5 million (the Deferred Precision Stock Payment), as an equity investment, for the purchase of&#160;220,712&#160;shares of Precision common stock&#160;calculated by dividing the Deferred Precision Stock Payment by 200% of the weighted average share price of the Precision common stock&#160;for the &lt;em style="font: inherit;"&gt;thirty&lt;/em&gt; (30) trading days preceding the payment date. The Deferred Precision Stock Payment which was classified as a forward contract liability in Other Current Liabilities as of &lt;em style="font: inherit;"&gt; December 31, 2024 &lt;/em&gt;was then reclassed to equity investments at its fair market value of $1.4 million on the date the payment was made to Precision.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;All Precision shares held are recognized at fair market value as of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;and&#160;are classified as an equity investment and included within long-term investments on the condensed consolidated balance sheet as of &lt;em style="font: inherit;"&gt; June 30, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Precision License Agreement also includes a milestone payment upon the achievement of a clinical and regulatory milestone event (Milestone Event &lt;em style="font: inherit;"&gt;1&lt;/em&gt;). Milestone Event &lt;em style="font: inherit;"&gt;1&lt;/em&gt; requires&#160;the Company to make a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time payment to Precision equal to $2.3 million (the Milestone &lt;em style="font: inherit;"&gt;1&lt;/em&gt; Precision Stock Payment). Upon receipt of the payment, Precision will issue to the Company shares of Precision common stock (rounded down to the nearest whole share) calculated by dividing the Milestone &lt;em style="font: inherit;"&gt;1&lt;/em&gt; Precision Stock Payment by 200% of the weighted average share price of the Precision common stock&#160;for the &lt;em style="font: inherit;"&gt;thirty&lt;/em&gt; (30) trading days preceding the achievement of Milestone Event &lt;em style="font: inherit;"&gt;1.&lt;/em&gt; While Milestone Event &lt;em style="font: inherit;"&gt;1&lt;/em&gt; has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been achieved to date, it was recorded to research and development&#160;License Fees as part of the cost of executing the Precision License Agreement, and is classified as a forward contract liability recognized at its fair market value of $1.4&#160;million in Other Current Liabilities on the Company&#x2019;s condensed consolidated balance sheet as of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, in accordance with ASC &lt;em style="font: inherit;"&gt;321.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5%&lt;/em&gt; Notes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;At the time of our merger (we were then known as Manhattan Pharmaceuticals,&#160;Inc. (Manhattan)) with Ariston Pharmaceuticals,&#160;Inc. (Ariston) in &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2010,&lt;/em&gt; Ariston issued $15.5 million of &lt;span style="-sec-ix-hidden:c133176563"&gt;five&lt;/span&gt;-year 5% notes payable (the &lt;em style="font: inherit;"&gt;5%&lt;/em&gt; Notes) in satisfaction of several note payable issuances. The &lt;em style="font: inherit;"&gt;5%&lt;/em&gt; Notes&#160;and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. We have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligations under the &lt;em style="font: inherit;"&gt;5%&lt;/em&gt; Notes&#160;aside from the conversion feature. The 5% Notes are recognized in other current liabilities&#160;on the Company&#x2019;s consolidated balance sheet as of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company&#x2019;s financial instruments include cash, cash equivalents consisting of money market funds, accounts receivable, accounts payable and loan payable. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, the fair values of cash and cash equivalents, restricted cash, accounts receivable,&#160;and loan and interest payable approximate their carrying value. The carrying value of the loan payable on the Company&#x2019;s balance sheet is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;Our equity investments classified as Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; were valued using their respective closing stock price on the Nasdaq Stock Market. We did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experience any transfers of financial instruments between the fair value hierarchy levels during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;. Our forward contract liabilities classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; were valued using Precision&#x2019;s closing stock price on the Nasdaq Stock Market and our assessment of the probability of achieving Milestone Event &lt;em style="font: inherit;"&gt;1.&lt;/em&gt; Our Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; instrument amounts represent the fair value of the &lt;em style="font: inherit;"&gt;5%&lt;/em&gt; Notes and related accrued interest.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following tables provide the fair value measurements of applicable financial assets and liabilities as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Financial assets and liabilities at fair value as of June 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Equity Investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forward Contract Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;5% Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Financial assets and liabilities at fair value as of December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity Investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forward Contract Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;5% Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,790&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The change in the fair value of the Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; assets and Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; and Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; liabilities is reported in other (income) expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
    <tgtx:LicenseAgreementAmountPaidUpfront
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176530"
      unitRef="USD">7500000</tgtx:LicenseAgreementAmountPaidUpfront>
    <tgtx:LicenseAgreementAmountPaidUpfrontCash
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-4"
      id="c133176531"
      unitRef="USD">5250000</tgtx:LicenseAgreementAmountPaidUpfrontCash>
    <tgtx:LicenseAgreementAmountPaidUpfrontEquityInvestment
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-4"
      id="c133176532"
      unitRef="USD">2250000</tgtx:LicenseAgreementAmountPaidUpfrontEquityInvestment>
    <tgtx:InvestmentPurchasedBalanceShares
      contextRef="d_2024-01-07_2024-01-07_RangeAxis-MaximumMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176533"
      unitRef="Share">2920816</tgtx:InvestmentPurchasedBalanceShares>
    <tgtx:InvestmentPurchasedBalancePricePerShare
      contextRef="i_2024-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176534"
      unitRef="USDPerShare">0.77</tgtx:InvestmentPurchasedBalancePricePerShare>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-02-01_2024-02-28_LegalEntityAxis-PrecisionBiosciencesIncMember_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c133176535"
      unitRef="Pure">30</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="d_2025-01-07_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="-5"
      id="c133176538"
      unitRef="USD">2500000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <tgtx:InvestmentPurchasedBalanceShares
      contextRef="d_2025-01-07_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176539"
      unitRef="Share">220712</tgtx:InvestmentPurchasedBalanceShares>
    <tgtx:LicenseAgreementPaymentPercentageOfWeightedAverageSharePrice
      contextRef="i_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="0"
      id="c133176540"
      unitRef="Pure">2</tgtx:LicenseAgreementPaymentPercentageOfWeightedAverageSharePrice>
    <tgtx:LicenseAgreementSharePriceTradingDays
      contextRef="d_2025-01-07_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      id="c133176542">P30D</tgtx:LicenseAgreementSharePriceTradingDays>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i_2025-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="-5"
      id="c133176543"
      unitRef="USD">1400000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <tgtx:LicenseAgreementMilestoneStockPayment
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176548"
      unitRef="USD">2300000</tgtx:LicenseAgreementMilestoneStockPayment>
    <tgtx:LicenseAgreementPaymentPercentageOfWeightedAverageSharePrice
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="0"
      id="c133176551"
      unitRef="Pure">2</tgtx:LicenseAgreementPaymentPercentageOfWeightedAverageSharePrice>
    <tgtx:LicenseAgreementSharePriceTradingDays
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      id="c133176553">P30D</tgtx:LicenseAgreementSharePriceTradingDays>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2025-06-30_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176557"
      unitRef="USD">1400000</tgtx:ForwardContractLiabilities>
    <us-gaap:NotesIssued1
      contextRef="d_2010-03-01_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember"
      decimals="-5"
      id="c133176562"
      unitRef="USD">15500000</us-gaap:NotesIssued1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember"
      decimals="2"
      id="c133176564"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember"
      decimals="INF"
      id="c133176567"
      unitRef="USDPerShare">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2010-03-31_BusinessAcquisitionAxis-ManhattanAndAristonPharmaceuticalsMergerMember"
      decimals="2"
      id="c133176570"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="d_2025-01-01_2025-06-30"
      id="EB49275B-E790-459C-BDCA-ABB4DE3B43C6">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Financial assets and liabilities at fair value as of June 30, 2025&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Equity Investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Forward Contract Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;5% Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,404&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Financial assets and liabilities at fair value as of December 31, 2024&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 1&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 2&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Level 3&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity Investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forward Contract Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;5% Notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,129&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,790&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176591"
      unitRef="USD">1336000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176592"
      unitRef="USD">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176593"
      unitRef="USD">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176594"
      unitRef="USD">1336000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176595"
      unitRef="USD">1336000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176596"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176597"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176598"
      unitRef="USD">1336000</us-gaap:AssetsFairValueDisclosure>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176599"
      unitRef="USD">0</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176600"
      unitRef="USD">1404000</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176601"
      unitRef="USD">0</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176602"
      unitRef="USD">1404000</tgtx:ForwardContractLiabilities>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176603"
      unitRef="USD">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176604"
      unitRef="USD">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-4"
      id="c133176605"
      unitRef="USD">810000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c133176606"
      unitRef="USD">810000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176607"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176608"
      unitRef="USD">1404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-4"
      id="c133176609"
      unitRef="USD">810000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176610"
      unitRef="USD">2214000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176619"
      unitRef="USD">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176620"
      unitRef="USD">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176621"
      unitRef="USD">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176622"
      unitRef="USD">371000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176623"
      unitRef="USD">371000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176624"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176625"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176626"
      unitRef="USD">371000</us-gaap:AssetsFairValueDisclosure>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176627"
      unitRef="USD">0</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176628"
      unitRef="USD">3129000</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176629"
      unitRef="USD">0</tgtx:ForwardContractLiabilities>
    <tgtx:ForwardContractLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176630"
      unitRef="USD">3129000</tgtx:ForwardContractLiabilities>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176631"
      unitRef="USD">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176632"
      unitRef="USD">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176633"
      unitRef="USD">661000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176634"
      unitRef="USD">661000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c133176635"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c133176636"
      unitRef="USD">3129000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c133176637"
      unitRef="USD">661000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c133176638"
      unitRef="USD">3790000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985510">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;6&lt;/em&gt; - STOCKHOLDERS&lt;/b&gt;&#x2019;&lt;b&gt; EQUITY &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more series. Upon issuance, we can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be greater than the rights of common stock.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Our amended and restated certificate of incorporation authorizes the issuance of up to 190,000,000 shares of $0.001 par value common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; September 2, 2022, &lt;/em&gt;we filed an automatic &#x201c;shelf registration&#x201d; statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; WKSI Shelf) as a &#x201c;well-known seasoned issuer&#x201d; as defined in Rule &lt;em style="font: inherit;"&gt;405&lt;/em&gt; under the Securities Act, which registered an unlimited and indeterminate amount of debt or equity securities for future issuance and sale. The &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; WKSI Shelf was declared effective in &lt;em style="font: inherit;"&gt; September 2022. &lt;/em&gt;In connection with the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; WKSI Shelf, we entered into an At-the-Market Issuance Sales Agreement (the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; ATM) with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc. (each a &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Agent and collectively, the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Agents), relating to the sale of shares of our common stock. Under the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; ATM, we will pay the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; WKSI Shelf is currently our only active shelf registration statement. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer any combination of the securities registered under the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; WKSI Shelf from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;need to file additional shelf registration statements in the future to provide us with the flexibility to raise additional capital to finance our operations as needed.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;b&gt;Share Repurchase Program and Treasury Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2024,&#160;&lt;/em&gt;we announced that our Board of Directors (the Board) had authorized and approved a share repurchase program for up to $100 million of the currently outstanding shares of the Company&#x2019;s common stock. Under the share repurchase program, we intend&#160;to repurchase shares through open market purchases, privately-negotiated transactions, block purchases or other methods in accordance with applicable federal securities laws, including Rule &lt;em style="font: inherit;"&gt;10b&lt;/em&gt;-&lt;em style="font: inherit;"&gt;18&lt;/em&gt; of the Securities Exchange Act of &lt;em style="font: inherit;"&gt;1934,&lt;/em&gt; as amended (the Exchange Act). For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the Company repurchased 193,500&#160;shares of common stock at a cost of $6.9&#160;million. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, 761,098&#160;shares of common stock are being held in Treasury, at a cost of approximately $22.0&#160;million, representing the fair market value on the date the shares were surrendered to the Company, mainly as part of our share repurchase program.&lt;/p&gt;
   &lt;p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Equity Incentive Plans&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The TG Therapeutics,&#160;Inc. Amended and Restated&#160;&lt;em style="font: inherit;"&gt;2012&lt;/em&gt;&#160;Incentive Plan (the&#160;&lt;em style="font: inherit;"&gt;2012&lt;/em&gt;&#160;Incentive Plan) was approved by stockholders in&#160;&lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&#160;As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;3,283,775 shares of restricted stock and&#160;2,099,816 options were outstanding, and&#160;no&#160;additional shares were available to be issued under the&#160;&lt;em style="font: inherit;"&gt;2012&lt;/em&gt;&#160;Incentive Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The TG Therapeutics, Inc.&#160;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;Incentive Plan (the&#160;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;Incentive Plan) was approved by stockholders in&#160;&lt;em style="font: inherit;"&gt; June 2022&#160;&lt;/em&gt;with&#160;17,000,000&#160;shares available to be issued. On &lt;em style="font: inherit;"&gt; June 12, 2025, &lt;/em&gt;the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Incentive Plan was amended to increase the shares available to be issued from 17,000,000 to 22,000,000 (the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Incentive Plan Amendment).&#160;As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;9,486,324&#160;shares of restricted stock and&#160;2,262,500&#160;options were outstanding, and up to an additional 6,567,583&#160;shares were available to be issued under the&#160;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&#160;Incentive Plan. The &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Incentive Plan is currently the Company's only active incentive plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Stock-based compensation expense included in the condensed consolidated statements of operations was&#160;$16.4&#160;million and $9.5&#160;million for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;,&#160;respectively, and $31.3&#160;million and $18.8&#160;million for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;.&#160;The&#160;$16.4&#160;million&#160;and the&#160;$31.3&#160;million for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;respectively, is net of $1.0&#160;million and $2.0&#160;million&#160;of stock-based compensation expense that was capitalized into inventory, respectively.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following table summarizes the activity for restricted stock for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; border-collapse: collapse; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Restricted Stock&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock awards outstanding, beginning of year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;11,843,586&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;9,639,068&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Changes during the year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,723,646&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3,636,606&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(1,604,013&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(1,644,884&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired or Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(193,120&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(258,107&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock awards outstanding, end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,770,099&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,372,683&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;div style="font-size: 10pt; text-align: justify; text-indent: 37pt;"&gt;
     Total stock-based compensation expense associated with restricted stock grants was
    $16.0&#160;million and
    $8.7&#160;million during the&#160;
    &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended
    &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, and is net of
    $1.0 million and
    $1.0 million of stock-based compensation expense that was capitalized into inventory during each of the respective periods. Total stock-based compensation expense associated with restricted stock grants was
    $30.5&#160;million and
    $17.2&#160;million for the
    &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, and is net of
    $2.0 million and
    $1.9 million of stock-based compensation expense that was capitalized into inventory during each of the respective periods. As of&#160;
    &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, there was approximately
    $68.3&#160;million of total unrecognized compensation expense related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of&#160;
    3.0&#160;years. This amount does&#160;
    &lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;include, as of&#160;
    &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;
    1,050,000&#160;shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones, and&#160;
    3,817,678 shares of restricted stock that vest based on market conditions. Milestone-based noncash compensation expense will be measured and recorded if and when a milestone becomes probable. Equity awards with market conditions are valued using advanced option-pricing models, such as a Monte Carlo simulation. The effect of a market condition is reflected in the award&#x2019;s fair value on the grant date. Stock-based compensation expense for an award that has a market condition is recognized over the requisite service period derived from the award valuation on the grant date, even if the market condition is never satisfied. As of&#160;
    &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;there was approximately
    $20.4&#160;million of total unrecognized compensation expense related to unvested milestone-based restricted stock. As of&#160;
    &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;there was approximately
    $46.1 million of total unrecognized compensation expense related to restricted stock with market conditions, which is expected to be recognized over a weighted-average period of
    2.3&#160;years.
   &lt;/div&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Stock Options:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The following table summarizes the activity for stock options for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock options outstanding, beginning of year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,470,216&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,697,029&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Changes during the year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(51,650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(29,750&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired or Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(56,250&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock options outstanding, end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,362,316&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,667,279&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Total stock based compensation expense associated with stock options was approximately $0.4&#160;million and $0.8&#160;million&#160;during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, and&#160;$0.8&#160;million and $1.6&#160;million for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively. As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;there was approximately $1.1 million of total unrecognized compensation cost related to unvested time-based stock options, which is expected to be recognized over a weighted-average period of&#160;0.8 years. As of&#160;&lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;stock options outstanding include options granted to both employees and non-employees which are both time-based and milestone-based. Stock-based compensation for milestone-based options will be recorded if and when a milestone becomes probable.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company&#x2019;s outstanding warrants as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;,&#160;are warrants issued to Hercules Capital, Inc. (Hercules) as part of the prior loan agreements to purchase&#160;115,042 and 50,172 shares of our common stock with exercise prices of $17.95 and $14.70, respectively. Please see Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for more information on our loan agreement with Hercules.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133176640"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133176641"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133176643"
      unitRef="Share">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133176644"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <tgtx:CommonStockCommissionRate
      contextRef="i_2022-09-02_SubsidiarySaleOfStockAxis-The2022AtmMember"
      decimals="2"
      id="c133176655"
      unitRef="Pure">0.03</tgtx:CommonStockCommissionRate>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i_2024-08-02_RangeAxis-MaximumMember"
      decimals="-8"
      id="c133176659"
      unitRef="USD">100000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c133176666"
      unitRef="Share">193500</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c133176667"
      unitRef="USD">6900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c133176668"
      unitRef="Share">761098</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i_2025-06-30"
      decimals="-6"
      id="c133176669"
      unitRef="USD">22000000</us-gaap:TreasuryStockValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2012IncentivePlanMember"
      decimals="INF"
      id="c133176674"
      unitRef="Share">3283775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30_PlanNameAxis-The2012IncentivePlanMember"
      decimals="INF"
      id="c133176675"
      unitRef="Share">2099816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-06-30_PlanNameAxis-The2012IncentivePlanMember"
      decimals="-3"
      id="c133176676"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2025-06-11_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176680"
      unitRef="Share">17000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2025-06-11_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176682"
      unitRef="Share">17000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2025-06-12_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176683"
      unitRef="Share">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176685"
      unitRef="Share">9486324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176686"
      unitRef="Share">2262500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-06-30_PlanNameAxis-The2022IncentivePlanMember"
      decimals="INF"
      id="c133176687"
      unitRef="Share">6567583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c133176691"
      unitRef="USD">16400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c133176692"
      unitRef="USD">9500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c133176695"
      unitRef="USD">31300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c133176696"
      unitRef="USD">18800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c133176699"
      unitRef="USD">16400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c133176700"
      unitRef="USD">31300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-6"
      id="c133176703"
      unitRef="USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-6"
      id="c133176704"
      unitRef="USD">2000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985511">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; border-collapse: collapse; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Restricted Stock&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock awards outstanding, beginning of year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;11,843,586&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;9,639,068&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Changes during the year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;2,723,646&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;3,636,606&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(1,604,013&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(1,644,884&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired or Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(193,120&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(258,107&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Restricted stock awards outstanding, end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,770,099&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,372,683&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176757"
      unitRef="Share">11843586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176758"
      unitRef="Share">9639068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176760"
      unitRef="Share">2723646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176761"
      unitRef="Share">3636606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176762"
      unitRef="Share">1604013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176763"
      unitRef="Share">1644884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176764"
      unitRef="Share">193120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176765"
      unitRef="Share">258107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176766"
      unitRef="Share">12770099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c133176767"
      unitRef="Share">11372683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-6"
      id="c133176706"
      unitRef="USD">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c133176707"
      unitRef="USD">8700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-6"
      id="c133176710"
      unitRef="USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-6"
      id="c133176711"
      unitRef="USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c133176712"
      unitRef="USD">30500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c133176713"
      unitRef="USD">17200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-6"
      id="c133176717"
      unitRef="USD">2000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c133176718"
      unitRef="USD">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-5"
      id="c133176719"
      unitRef="USD">68300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      id="c133176720">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-06-30_AwardTypeAxis-MilestoneBasedRestrictedStockMember"
      decimals="INF"
      id="c133176722"
      unitRef="Share">1050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-06-30_AwardTypeAxis-MarketbasedRestrictedStockMember"
      decimals="INF"
      id="c133176723"
      unitRef="Share">3817678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-06-30_AwardTypeAxis-MilestoneBasedRestrictedStockMember"
      decimals="-5"
      id="c133176724"
      unitRef="USD">20400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-06-30_AwardTypeAxis-MarketbasedRestrictedStockMember"
      decimals="-5"
      id="c133176725"
      unitRef="USD">46100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-MarketbasedRestrictedStockMember"
      id="c133176726">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985512">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt; width: 70%;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock options outstanding, beginning of year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,470,216&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;4,697,029&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Changes during the year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(51,650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;"&gt;(29,750&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Expired or Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(56,250&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-size: 10pt;"&gt; &lt;p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Stock options outstanding, end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,362,316&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,667,279&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c133176774"
      unitRef="Share">4470216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c133176775"
      unitRef="Share">4697029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176778"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176779"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176780"
      unitRef="Share">51650</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176781"
      unitRef="Share">29750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2025-01-01_2025-06-30"
      decimals="INF"
      id="c133176782"
      unitRef="Share">56250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c133176783"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30"
      decimals="0"
      id="c133176784"
      unitRef="Share">4362316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-06-30"
      decimals="0"
      id="c133176785"
      unitRef="Share">4667279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c133176729"
      unitRef="USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c133176730"
      unitRef="USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c133176733"
      unitRef="USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c133176734"
      unitRef="USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c133176737"
      unitRef="USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c133176738">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockAmendedLoanAgreementMember"
      decimals="INF"
      id="c133176739"
      unitRef="Share">115042</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockFirstAmendmentLoanAgreementMember"
      decimals="INF"
      id="c133176740"
      unitRef="Share">50172</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockAmendedLoanAgreementMember"
      decimals="INF"
      id="c133176741"
      unitRef="USDPerShare">17.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockFirstAmendmentMember"
      decimals="INF"
      id="c133176742"
      unitRef="USDPerShare">14.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LongTermDebtTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985513">
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;7&lt;/em&gt; - LOAN PAYABLE&#160;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company entered into a term loan facility of $250&#160;million (the Initial Term Loan) with Blue Owl Capital Corporation, as administrative agent (the Administrative Agent), HealthCare Royalty and Blue Owl Capital under the Financing Agreement (as defined below). The Company repaid all outstanding principal and accrued interest and fees under the prior loan agreement with Hercules (such repayment, the Refinancing), which Refinancing was funded with the proceeds of the Initial Term Loan.&#160;The agreement with Hercules was effectively terminated, and all guarantees and liens granted thereunder were released upon the consummation of the Refinancing.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Initial Term Loan is governed by a financing agreement (the Financing Agreement), which provides for (i) a single draw of the Initial Term Loan on the New Closing Date and (ii) an uncommitted additional facility in an aggregate principal amount of up to $100&#160;million. The Initial Term Loan will mature on&#160;&lt;em style="font: inherit;"&gt; August 2, 2029 (&lt;/em&gt;the Term Loan Maturity Date). The Initial Term Loan accrues interest at a per annum rate of interest equal to an applicable margin plus, at the Company&#x2019;s option, either (a) at a base rate determined by reference to the highest of (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the prime rate published by the Wall Street Journal, (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the federal funds effective rate plus&#160;0.50% and (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) Term SOFR, plus&#160;1.00% or (b) Term SOFR, which, shall be&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;less than&#160;1.00%. The applicable margin for borrowings of the Initial Term Loan is determined on a quarterly basis by reference to a pricing grid based on the achievement of US Net Sales (as defined in the Financing Agreement) for the most recently completed&#160;&lt;em style="font: inherit;"&gt;four&lt;/em&gt;&#160;consecutive fiscal quarters of the Company and its Subsidiaries (as defined in the Financing Agreement). The pricing grid commences at&#160;5.50% for SOFR borrowings and&#160;4.50% for base rate borrowings and is subject to a&#160;25&#160;basis point step-down upon achievement of a specified US Net Sales threshold. The Initial Term Loan requires scheduled quarterly amortization payments, commencing with the fiscal quarter ending&#160;&lt;em style="font: inherit;"&gt; June 30, 2028,&#160;&lt;/em&gt;in an amount equal to $12.5&#160;million, with the balance due and payable on the Term Loan Maturity Date&#x37e; provided that such amortization payments&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;be deferred to the Term Loan Maturity Date upon the achievement of a Total Net Leverage Ratio (as defined in the Financing Agreement) that is less than or equal to an agreed threshold.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Initial Term Loan is secured by a lien on substantially all of the assets of the Company and certain subsidiaries of the Company as guarantors and contains customary covenants and representations. The events of default under the Financing Agreement are customary for financings of this type. If an event of default occurs, the Administrative Agent is entitled to take enforcement action, including acceleration of amounts due under the Financing Agreement. The Company capitalized&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;&#160;party fees from the Initial Term Loan to debt issuance costs and capitalized the facility fee incurred with the Administrative Agent as part of the Initial Term Loan to debt discount.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company incurred total financing and upfront costs of $6.0 million related to the Initial Term Loan which are recorded as debt issuance costs and debt discount costs&#160;and as an offset to loan payable on the Company&#x2019;s consolidated balance sheet. The debt issuance and debt discount costs are being amortized over the term of the debt using the straight-line method, which approximates the effective interest method, and will be included in interest expense in the Company&#x2019;s consolidated statements of operations. Amortization of debt issuance and debt discount costs was $0.6&#160;million and $1.3&#160;million for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively. At &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the remaining unamortized balance of debt issuance and discount costs was approximately&#160;$5.0&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The loan payable balance of the Initial Term Loan as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, is as follows:&lt;/p&gt;
   &lt;p style="text-indent: 9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;The Initial Term Loan&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;The Initial Term Loan&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loan payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Add: Accreted Liability of final payment fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: unamortized debt issuance and debt discount costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: principal payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total loan payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loan payable non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160; &#160;&lt;/p&gt;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-7"
      id="c133176788"
      unitRef="USD">250000000</us-gaap:DebtInstrumentFaceAmount>
    <tgtx:DebtInstrumentUncommittedAdditionalBorrowingFacilityPrincipal
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-8"
      id="c133176789"
      unitRef="USD">100000000</tgtx:DebtInstrumentUncommittedAdditionalBorrowingFacilityPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-FederalFundsEffectiveSwapRateMember"
      decimals="3"
      id="c133176792"
      unitRef="Pure">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"
      decimals="2"
      id="c133176794"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <tgtx:DebtInstrumentTermSofrMinimum
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="2"
      id="c133176796"
      unitRef="Pure">0.01</tgtx:DebtInstrumentTermSofrMinimum>
    <tgtx:DebtInstrumentPricingGridPercentageForBorrowing
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-SecuredOvernightFinancingRateSofrMember"
      decimals="3"
      id="c133176798"
      unitRef="Pure">0.055</tgtx:DebtInstrumentPricingGridPercentageForBorrowing>
    <tgtx:DebtInstrumentPricingGridPercentageForBorrowing
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember_VariableRateAxis-BaseRateMember"
      decimals="3"
      id="c133176799"
      unitRef="Pure">0.045</tgtx:DebtInstrumentPricingGridPercentageForBorrowing>
    <tgtx:DebtInstrumentPricingGridStepdownUponAchievementOfSpecificThresholdPercentage
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="4"
      id="c133176800"
      unitRef="Pure">0.0025</tgtx:DebtInstrumentPricingGridStepdownUponAchievementOfSpecificThresholdPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="d_2024-08-02_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-5"
      id="c133176801"
      unitRef="USD">12500000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i_2024-08-02_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-6"
      id="c133176803"
      unitRef="USD">6000000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2025-01-01_2025-06-30_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-5"
      id="c133176804"
      unitRef="USD">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2024-01-01_2024-06-30_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-5"
      id="c133176805"
      unitRef="USD">1300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2025-06-30_DebtInstrumentAxis-InitialTermLoanMember"
      decimals="-6"
      id="c133176808"
      unitRef="USD">5000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985514">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;The Initial Term Loan&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;The Initial Term Loan&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loan payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Add: Accreted Liability of final payment fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: unamortized debt issuance and debt discount costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,963&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,571&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: principal payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total loan payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loan payable non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;245,037&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;244,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-7"
      id="c133176824"
      unitRef="USD">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-7"
      id="c133176825"
      unitRef="USD">250000000</us-gaap:DebtInstrumentFaceAmount>
    <tgtx:LongTermDebtAccretedLiabilityOfFinalPaymentFee
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176826"
      unitRef="USD">0</tgtx:LongTermDebtAccretedLiabilityOfFinalPaymentFee>
    <tgtx:LongTermDebtAccretedLiabilityOfFinalPaymentFee
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176827"
      unitRef="USD">0</tgtx:LongTermDebtAccretedLiabilityOfFinalPaymentFee>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-7"
      id="c133176828"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-7"
      id="c133176829"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176830"
      unitRef="USD">4963000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176831"
      unitRef="USD">5571000</us-gaap:UnamortizedDebtIssuanceExpense>
    <tgtx:LongtermDebtBeforeRepayments
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176832"
      unitRef="USD">245037000</tgtx:LongtermDebtBeforeRepayments>
    <tgtx:LongtermDebtBeforeRepayments
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176833"
      unitRef="USD">244429000</tgtx:LongtermDebtBeforeRepayments>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="d_2025-01-01_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176834"
      unitRef="USD">-0</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="d_2024-01-01_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176835"
      unitRef="USD">-0</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:LoansPayable
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176836"
      unitRef="USD">245037000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176837"
      unitRef="USD">244429000</us-gaap:LoansPayable>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176838"
      unitRef="USD">-0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176839"
      unitRef="USD">-0</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="i_2025-06-30_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176840"
      unitRef="USD">245037000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="i_2024-12-31_DebtInstrumentAxis-TheFirstAmendmentTermLoanMember"
      decimals="-3"
      id="c133176841"
      unitRef="USD">244429000</us-gaap:LongTermLoansPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985515">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;8&lt;/em&gt; - LEASES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2014, &lt;/em&gt;we entered into an agreement (the Office Agreement) with Fortress Biotech, Inc. (FBIO) to occupy approximately 45% of the 24,000 square feet of New York City office space leased by FBIO. The Office Agreement requires us to pay our respective share of the average annual rent and other costs of the 15-year lease. We approximate an average annual rental obligation of $1.8 million under the Office Agreement. In connection with the Office Agreement, we have pledged $1.3 million to secure a line of credit as a security deposit for the Office Agreement, which has been recorded as restricted cash in the accompanying condensed consolidated balance sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; October 2021, &lt;/em&gt;we finalized a &lt;span style="-sec-ix-hidden:c133176848"&gt;five&lt;/span&gt;-year lease for office space in North Carolina (the NC Lease). We approximate an average annual rental obligation of $0.2 million under the NC Lease. We incurred rental expense of less than&#160;$0.1&#160;million for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The present values of our lease liability and corresponding Right-of-Use (ROU) asset are $8.7&#160;million&#160;and $6.7&#160;million, respectively, as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;. Our leases have remaining lease terms of &lt;span style="-sec-ix-hidden:c133176854"&gt;two&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c133176855"&gt;six&lt;/span&gt; years. One lease has a renewal option to extend the lease for an additional term of &lt;span style="-sec-ix-hidden:c133176856"&gt;two&lt;/span&gt; years. The following components of lease expense are included in the Company&#x2019;s condensed consolidated statements of operations for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;474&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,151&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;474&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,151&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the weighted-average remaining operating lease term was 5.2&#160;years and the weighted-average discount rate for operating leases was 10.07%. Cash&#160;paid&#160;for amounts included in the measurement of operating lease liabilities during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; was $1.1&#160;million. The balance sheet classification of lease liabilities was as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Lease liability current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,091&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,157&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Lease liability non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,588&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,133&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"&gt;Total lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the maturities of lease liabilities were as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Remainder of 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,037&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;2,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,913&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,827&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,827&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;After 2030&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,889&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Less: interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,894&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities(*)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;"&gt;&#160;&lt;/p&gt;
   &lt;hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 0pt auto 0pt 0pt;"/&gt;
   &lt;p style="margin: 0pt; font-size: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(*)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;As our leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date and considering the term of the lease to determine the present value of lease payments. We used the incremental borrowing rate of 10.25% on &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;28,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; for operating leases that commenced prior to that date through &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;We used an incremental borrowing rate of 5.65% for the NC lease.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <tgtx:PercentageOfOccupancy
      contextRef="d_2014-10-01_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember"
      decimals="2"
      id="c133176843"
      unitRef="Pure">0.45</tgtx:PercentageOfOccupancy>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember"
      decimals="INF"
      id="c133176844"
      unitRef="SquareFoot">24000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember"
      id="c133176845">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <tgtx:AverageAnnualRentalPayments
      contextRef="d_2014-10-01_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember"
      decimals="-5"
      id="c133176846"
      unitRef="USD">1800000</tgtx:AverageAnnualRentalPayments>
    <us-gaap:RestrictedCash
      contextRef="i_2014-10-31_RelatedPartyTransactionAxis-OfficeAgreementWithFortressBiotechMember_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-DepositForOfficeAgreementMember"
      decimals="-5"
      id="c133176847"
      unitRef="USD">1300000</us-gaap:RestrictedCash>
    <tgtx:AverageAnnualRentalPayments
      contextRef="d_2021-10-01_2021-10-31_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember"
      decimals="-5"
      id="c133176849"
      unitRef="USD">200000</tgtx:AverageAnnualRentalPayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember"
      decimals="-5"
      id="c133176850"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-06-30_RelatedPartyTransactionAxis-OfficeAgreementMember"
      decimals="-5"
      id="c133176852"
      unitRef="USD">8700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-06-30_RelatedPartyTransactionAxis-OfficeAgreementMember"
      decimals="-5"
      id="c133176853"
      unitRef="USD">6700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985516">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;474&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,151&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;474&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;978&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,151&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176883"
      unitRef="USD">474000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133176884"
      unitRef="USD">551000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176885"
      unitRef="USD">978000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176886"
      unitRef="USD">1151000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c133176887"
      unitRef="USD">474000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c133176888"
      unitRef="USD">551000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-3"
      id="c133176889"
      unitRef="USD">978000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c133176890"
      unitRef="USD">1151000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2025-06-30" id="c133176860">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2025-06-30"
      decimals="4"
      id="c133176861"
      unitRef="Pure">0.1007</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c133176863"
      unitRef="USD">1100000</us-gaap:OperatingLeasePayments>
    <tgtx:ScheduleOfBalanceSheetClassificationOfOperatingLeaseTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985517">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2025&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Lease liability current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,091&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,157&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Lease liability non-current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,588&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,133&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"&gt;Total lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </tgtx:ScheduleOfBalanceSheetClassificationOfOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176896"
      unitRef="USD">1091000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176897"
      unitRef="USD">1157000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176898"
      unitRef="USD">7588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c133176899"
      unitRef="USD">8133000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176900"
      unitRef="USD">8679000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c133176901"
      unitRef="USD">9290000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985518">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#x200b;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Operating&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;(in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;leases&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Remainder of 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,037&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;2,080&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,913&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2028&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,827&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;2029&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;1,827&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;After 2030&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,889&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"&gt;Less: interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,894&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of lease liabilities(*)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176904"
      unitRef="USD">1037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c133176905"
      unitRef="USD">2080000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176906"
      unitRef="USD">1913000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176907"
      unitRef="USD">1827000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176908"
      unitRef="USD">1827000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <tgtx:LesseeOperatingLeaseLiabilityToBePaidYearFiveAndTherafter
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176909"
      unitRef="USD">2889000</tgtx:LesseeOperatingLeaseLiabilityToBePaidYearFiveAndTherafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176910"
      unitRef="USD">11573000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176911"
      unitRef="USD">2894000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c133176912"
      unitRef="USD">8679000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2019-02-28"
      decimals="4"
      id="c133176866"
      unitRef="Pure">0.1025</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2021-12-31_TypeOfArrangementAxis-TheNorthCarolinaLeaseMember"
      decimals="4"
      id="c133176869"
      unitRef="Pure">0.0565</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <tgtx:LicenseAgreementDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985519">
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;b&gt;NOTE &lt;em style="font: inherit;"&gt;9&lt;/em&gt; - LICENSE AGREEMENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;BRIUMVI (Ublituximab)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2012, &lt;/em&gt;we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the LFB License Agreement). Under the terms of the LFB License Agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of ublituximab. From the inception of the LFB&#160;License Agreement, we have incurred expenses of&#160;approximately $31.0&#160;million related to the achievement of certain milestones of the LFB License Agreement. No further milestone payments remain payable under the LFB License Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;LFB Group is eligible to receive royalty payments on net sales of ublituximab at a royalty rate that escalates from mid-single digits to high-single digits. The license will terminate on a country-by-country basis upon the expiration of the last licensed patent right or &lt;span style="-sec-ix-hidden:c133176916"&gt;fifteen&lt;/span&gt; years after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of a product in such country, unless the agreement is earlier terminated (i) by LFB if the Company challenges any of the licensed patent rights, (ii) by either party due to a breach of the agreement, or (iii) by either party in the event of the insolvency of the other party. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the Company recorded $14.2 million and $26.2 million, respectively,&#160;related to the worldwide royalty due under the LFB License Agreement in cost of revenue. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, $14.2 million in royalties payable under the LFB License Agreement remain&#160;outstanding in accounts payable and accrued expenses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2012, &lt;/em&gt;we entered into an exclusive (within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd. (Ildong) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;An upfront payment of $2.0 million, which was received in &lt;em style="font: inherit;"&gt; December 2012, &lt;/em&gt;net of $0.3 million of income tax withholdings, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or &lt;span style="-sec-ix-hidden:c133176925"&gt;fifteen&lt;/span&gt; years after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $38,000 for each of the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;. At &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2024&lt;/em&gt;, we have deferred revenue of approximately $0.1&#160;million and $0.2&#160;million, respectively, associated with this $2.0 million payment.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of ublituximab in the sublicense territory.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;b&gt;Neuraxpharm Commercialization Agreement&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; July 2023, &lt;/em&gt;the Company entered into the Commercialization Agreement with Neuraxpharm. The Company granted Neuraxpharm the exclusive right to commercialize BRIUMVI in certain territories outside the United States, Canada, and Mexico, the commercialization rights for which had been previously retained by the Company, thus, and excluding certain Asian countries subject to previously existing partnerships. Under the terms of the Commercialization Agreement, the Company received a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time, non-refundable payment of $140.0 million upon contract execution and a $12.5&#160;million milestone payment&#160;upon the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;key market commercial launch in the EU. The Company is eligible to receive up to an additional $492.5&#160;million in milestone-based payments on achievement of certain launch and commercial milestones. In addition, TG will receive tiered double-digit royalties on net product sales up to&#160;30%. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, royalty revenue of $1.1&#160;million and $1.7&#160;million, respectively,&#160;was recognized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company evaluated the Commercialization Agreement under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; and concluded that Neuraxpharm represents a customer in the transaction. In accordance with this guidance, the Company identified the following commitments under the arrangement: (i) the exclusive right to develop, sell, offer to sell and import the Product in the Territory (the License); (ii) certain development and regulatory activities (Development and Regulatory Activities).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The arrangement also provides Neuraxpharm with the right to make optional purchases of BRIUMVI (the Supply of Licensed Product). These optional purchases are accounted for as a separate contract when the right to purchase BRIUMVI is exercised. The consideration for optional purchases of BRIUMVI by Neuraxpharm approximates the price that a customer in the Territory would be willing to pay for these goods.&#160;The performance obligation related to the Supply of Licensed Product is met when control of the product passes to Neuraxpharm. The consideration received from Neuraxpharm for the supply of BRIUMVI will be recognized by the Company as a component of product revenue, net.&#160;As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the Company has an unconditional right to receive $1.5&#160;million in consideration from Neuraxpharm related to the performance obligation to supply BRIUMVI, that is recorded as accounts receivable, net. The related performance obligation to supply BRIUMVI has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been satisfied, and therefore, as of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, $25.5 million has been recorded as deferred revenue. The Company will reevaluate the consideration received, and performance obligations satisfied, at the end of each reporting period. Such reevaluations &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a change to the amount of product revenue, net, recognized and deferred revenue.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;"&gt;&lt;b&gt;Azer-cel&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into the Precision License Agreement&#160;with Precision, pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision&#x2019;s allogeneic CAR T therapy azercabtagene zapreleucel (azer-cel) for the treatment of autoimmune and other non-oncology diseases and conditions.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Pursuant to the Precision License Agreement, the Company made an upfront payment to Precision of $7.5 million, consisting of (i) $5.25 million in cash and (ii) $2.25 million, as an equity investment, for the purchase of 2,920,816 shares of Precision&#x2019;s common stock at a price of $0.77 per share. In &lt;em style="font: inherit;"&gt; January 2025, &lt;/em&gt;within &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months of the Precision License Agreement, the Company made a deferred payment of $2.5 million to Precision consisting of an equity investment in Precision&#x2019;s common stock at a 100% premium to the 30-day volume-weighted average price (the &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day VWAP) prior to purchase. Upon receipt of such payment, Precision issued to the Company 220,712 shares of Precision common stock. Upon achievement of certain near-term clinical or time-based milestones, the Company will make a $7.5 million payment to Precision, a portion of which will also be an equity investment in Precision&#x2019;s common stock at a 100% premium to the 30-day VWAP prior to purchase. Precision will be eligible to receive up to $288 million in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones. In addition, the Company is obligated to pay Precision high-single-digit to low-double-digit royalties on net sales of the licensed product on a country-by-country basis until the latest to occur of patent expiration, loss of regulatory exclusivity, and a period of &lt;span style="-sec-ix-hidden:c133176967"&gt;ten&lt;/span&gt; years following the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of the licensed product in such country. As of &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of the near-term clinical milestones have been achieved.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;MaxCyte&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; February 10, 2025, &lt;/em&gt;the Company entered into the Strategic Platform License Agreement with MaxCyte, Inc. which granted a non-exclusive, non-transferable license for the Company to use MaxCyte&#x2019;s cell loading technology (&#x201c;licensed technology&#x201d;) to develop and commercialize products for the treatment of autoimmune and other non-oncology diseases and conditions, including azer-cel, which was licensed by the Company from Precision in &lt;em style="font: inherit;"&gt; January 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;MaxCyte, Inc. is eligible to receive royalty payments on net sales of approved products developed with the licensed technology at a royalty rate in the low-single digits.&#160;Upon the achievement of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; dosing of a human subject in a pivotal trial for a product developed with the licensed technology the Company will make a $1.0 million payment to MaxCyte, Inc.&#160;MaxCyte, Inc. will also be eligible to receive up to $13 million in additional milestone payments based on the achievement of certain regulatory marketing approvals.&#160;The Company is also required to pay an annual licensing fee of approximately $0.2 million for access to the licensed technology.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The Strategic Platform License Agreement will expire on the &lt;span style="-sec-ix-hidden:c133176975"&gt;ten&lt;/span&gt;-year anniversary if the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the milestone events prior to that date.&#160;The Company will have the option, at its sole discretion, to extend the term of the Strategic Platform License Agreement beyond the initial &lt;span style="-sec-ix-hidden:c133176978"&gt;ten&lt;/span&gt; years for successive renewal terms of &lt;span style="-sec-ix-hidden:c133176979"&gt;five&lt;/span&gt; years each, as long as all applicable licensing fees and milestone payments have been paid timely and the Company provides MaxCyte, Inc. at least &lt;span style="-sec-ix-hidden:c133176980"&gt;ninety&lt;/span&gt; days written notice prior to the expiration of the then-current term.&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </tgtx:LicenseAgreementDisclosureTextBlock>
    <tgtx:LicenseAndCollaborationAgreementExpensesIncurred
      contextRef="d_2012-01-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      decimals="-6"
      id="c133176914"
      unitRef="USD">31000000</tgtx:LicenseAndCollaborationAgreementExpensesIncurred>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      decimals="-3"
      id="c133176915"
      unitRef="USD">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RoyaltyExpense
      contextRef="d_2025-04-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      decimals="-5"
      id="c133176920"
      unitRef="USD">14200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      decimals="-5"
      id="c133176921"
      unitRef="USD">26200000</us-gaap:RoyaltyExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i_2025-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember_TypeOfArrangementAxis-LFBLicenseAgreementMember"
      decimals="-5"
      id="c133176922"
      unitRef="USD">14200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <tgtx:UpfrontFeeReceivedFromSubLicense
      contextRef="d_2012-12-01_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-6"
      id="c133176923"
      unitRef="USD">2000000</tgtx:UpfrontFeeReceivedFromSubLicense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2012-12-01_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-5"
      id="c133176924"
      unitRef="USD">300000</us-gaap:IncomeTaxExpenseBenefit>
    <tgtx:LicenseRevenue
      contextRef="d_2025-04-01_2025-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="INF"
      id="c133176927"
      unitRef="USD">38000</tgtx:LicenseRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i_2025-06-30_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-5"
      id="c133176930"
      unitRef="USD">100000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i_2024-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-5"
      id="c133176931"
      unitRef="USD">200000</us-gaap:DeferredRevenue>
    <tgtx:UpfrontFeeReceivedFromSubLicense
      contextRef="d_2012-12-01_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-6"
      id="c133176932"
      unitRef="USD">2000000</tgtx:UpfrontFeeReceivedFromSubLicense>
    <tgtx:AdditionalAmountReceivableOnAchievementOfPrespecifiedMilestones
      contextRef="i_2012-12-31_TypeOfArrangementAxis-SublicenseAgreementWithIldongPharmaceuticalCoMember"
      decimals="-6"
      id="c133176933"
      unitRef="USD">5000000</tgtx:AdditionalAmountReceivableOnAchievementOfPrespecifiedMilestones>
    <tgtx:LicenseAndCollaborationAgreementsOnetimeNonrefundablePayment
      contextRef="d_2023-07-28_2023-07-28_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-7"
      id="c133176936"
      unitRef="USD">140000000</tgtx:LicenseAndCollaborationAgreementsOnetimeNonrefundablePayment>
    <tgtx:ProductSalesNetRelatedToPerformanceObligations
      contextRef="i_2023-07-28_ProductOrServiceAxis-ProductMember_TypeOfArrangementAxis-BriumviUblituximabMember"
      decimals="-5"
      id="c133176937"
      unitRef="USD">12500000</tgtx:ProductSalesNetRelatedToPerformanceObligations>
    <tgtx:AdditionalAmountReceivableOnAchievementOfPrespecifiedMilestones
      contextRef="i_2023-07-28_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176939"
      unitRef="USD">492500000</tgtx:AdditionalAmountReceivableOnAchievementOfPrespecifiedMilestones>
    <tgtx:RoyaltyPercentageOnNetProductSales
      contextRef="d_2023-07-28_2023-07-28_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="1"
      id="c133176940"
      unitRef="Pure">0.30</tgtx:RoyaltyPercentageOnNetProductSales>
    <us-gaap:Revenues
      contextRef="d_2025-04-01_2025-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176944"
      unitRef="USD">1100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-04-01_2024-06-30_ProductOrServiceAxis-RoyaltyMember_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176945"
      unitRef="USD">1700000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2025-06-30_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176947"
      unitRef="USD">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DeferredRevenue
      contextRef="i_2025-06-30_TypeOfArrangementAxis-CommercializationAgreementWithNeuraxpharmMember"
      decimals="-5"
      id="c133176950"
      unitRef="USD">25500000</us-gaap:DeferredRevenue>
    <tgtx:LicenseAgreementAmountPaidUpfront
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176952"
      unitRef="USD">7500000</tgtx:LicenseAgreementAmountPaidUpfront>
    <tgtx:LicenseAgreementAmountPaidUpfrontCash
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-4"
      id="c133176953"
      unitRef="USD">5250000</tgtx:LicenseAgreementAmountPaidUpfrontCash>
    <tgtx:LicenseAgreementAmountPaidUpfrontEquityInvestment
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-4"
      id="c133176954"
      unitRef="USD">2250000</tgtx:LicenseAgreementAmountPaidUpfrontEquityInvestment>
    <tgtx:InvestmentPurchasedBalanceShares
      contextRef="d_2024-01-07_2024-01-07_RangeAxis-MaximumMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176955"
      unitRef="Share">2920816</tgtx:InvestmentPurchasedBalanceShares>
    <tgtx:InvestmentPurchasedBalancePricePerShare
      contextRef="i_2024-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176956"
      unitRef="USDPerShare">0.77</tgtx:InvestmentPurchasedBalancePricePerShare>
    <tgtx:LicenseAgreementDeferredPayment
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176958"
      unitRef="USD">2500000</tgtx:LicenseAgreementDeferredPayment>
    <tgtx:LicenseAgreementPercentageOfPremiumOnEquityInvestment
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="0"
      id="c133176959"
      unitRef="Pure">1</tgtx:LicenseAgreementPercentageOfPremiumOnEquityInvestment>
    <tgtx:LicenseAgreementSharePriceTradingDays
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      id="c133176960">P30D</tgtx:LicenseAgreementSharePriceTradingDays>
    <tgtx:InvestmentPurchasedBalanceShares
      contextRef="d_2024-01-07_2024-01-07_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrecisionBiosciencesIncMember"
      decimals="INF"
      id="c133176962"
      unitRef="Share">220712</tgtx:InvestmentPurchasedBalanceShares>
    <tgtx:LicenseAgreementAmountPaidUpfront
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-5"
      id="c133176963"
      unitRef="USD">7500000</tgtx:LicenseAgreementAmountPaidUpfront>
    <tgtx:LicenseAgreementPercentageOfPremiumOnEquityInvestment
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="0"
      id="c133176964"
      unitRef="Pure">1</tgtx:LicenseAgreementPercentageOfPremiumOnEquityInvestment>
    <tgtx:LicenseAgreementSharePriceTradingDays
      contextRef="d_2024-01-07_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      id="c133176965">P30D</tgtx:LicenseAgreementSharePriceTradingDays>
    <tgtx:LicenseAgreementAdditionalMilestonePayments
      contextRef="i_2024-01-07_TypeOfArrangementAxis-PrecisionLicenseAgreementMember"
      decimals="-6"
      id="c133176966"
      unitRef="USD">288000000</tgtx:LicenseAgreementAdditionalMilestonePayments>
    <tgtx:LicenseAgreementAmountPaidUpfront
      contextRef="d_2025-02-10_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      decimals="-6"
      id="c133176972"
      unitRef="USD">1000000</tgtx:LicenseAgreementAmountPaidUpfront>
    <tgtx:LicenseAgreementAdditionalMilestonePayments
      contextRef="i_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      decimals="-6"
      id="c133176973"
      unitRef="USD">13000000</tgtx:LicenseAgreementAdditionalMilestonePayments>
    <tgtx:LicensingAgreementAnnualLicenseFee
      contextRef="i_2025-02-10_TypeOfArrangementAxis-StrategicPlatformLicenseAgreementWithMaxcyteIncMember"
      decimals="-5"
      id="c133176974"
      unitRef="USD">200000</tgtx:LicensingAgreementAnnualLicenseFee>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985520">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;10&lt;/em&gt; - RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2015,&lt;/em&gt; we entered into a Shared Services Agreement (the Shared Services Agreement) with FBIO to share the cost of certain services such as facilities use, personnel costs and other overhead and administrative costs. The Shared Services Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we incurred expenses of approximately $0.8&#160;million and $0.9&#160;million for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, respectively, primarily related to shared personnel. Mr.&#160;Weiss, our&#160;Chairman and Chief Executive Officer,&#160;also serves as a director and Executive Vice Chairman, Strategic Development of FBIO.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Please refer to Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x2013; Leases for details regarding the Office Agreement with FBIO.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c133176994"
      unitRef="USD">800000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c133176995"
      unitRef="USD">900000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985521">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;NOTE&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;11&lt;/em&gt;&#160;- INCOME TAXES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, the Company recorded income tax expense of $3.1&#160;million and income tax benefit of&#160;$0.3&#160;million, respectively. The effective tax rates for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;were&#160;8.6%&#160;and 7.2%, respectively. For the&#160;&lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, the effective tax rate differs from the federal statutory rate primarily due state income taxes, research and development tax credit and change in valuation allowance. For the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the effective tax rate differs from the federal statutory rate primarily due to state income taxes and research and development credit.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;, the Company recorded income tax expense of&#160;$2.7&#160;million&#160;and income tax benefit of $0.3&#160;million, respectively. The effective tax rates for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;were 8.8%&#160;and (5.0)%, respectively. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;,&#160;the effective tax rate differs from the federal statutory rate primarily due state income taxes, research and development tax credit, non-deductible officer compensation and change in valuation allowance.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; July 4, 2025, &lt;/em&gt;the One Big Beautiful Bill Act (the &#x201c;OBBBA&#x201d;) was enacted in the United States. The OBBBA includes significant changes to federal tax law and other regulatory provisions that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;impact the Company. As the legislation was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; signed into law until the Company&#x2019;s &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2025,&lt;/em&gt; the impacts are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in its operating results for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025. &lt;/em&gt;The Company plans to&#160;evaluate the impact of the newly enacted tax law, including&#160;its impact on the Company&#x2019;s forecasted annual effective tax rate in subsequent periods as required.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-06-30"
      decimals="-5"
      id="c133177002"
      unitRef="USD">3100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c133177003"
      unitRef="USD">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-01-01_2025-06-30"
      decimals="3"
      id="c133177006"
      unitRef="Pure">0.086</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-06-30"
      decimals="3"
      id="c133177007"
      unitRef="Pure">0.072</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c133177012"
      unitRef="USD">2700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c133177013"
      unitRef="USD">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-04-01_2025-06-30"
      decimals="3"
      id="c133177016"
      unitRef="Pure">0.088</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-04-01_2024-06-30"
      decimals="2"
      id="c133177017"
      unitRef="Pure">-0.05</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-06-30" id="c2985522">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="otherinfo" title="otherinfo"&gt;&lt;/a&gt;ITEM &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; OTHER INFORMATION.&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Securities Trading Plans of Directors and Executive Officers&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c133177029"&gt;&lt;span style="-sec-ix-hidden:c133177035"&gt;&lt;span style="-sec-ix-hidden:c133177036"&gt;&lt;span style="-sec-ix-hidden:c133177037"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of the Company&#x2019;s securities that was intended to satisfy the affirmative defense conditions of Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(c) or any &#x201c;non-Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement,&#x201d; as each term is defined in Item &lt;em style="font: inherit;"&gt;408&lt;/em&gt;(a) of Regulation S-K.&lt;/p&gt;
  </ecd:MtrlTermsOfTrdArrTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c133176912"
          xlink:label="c133176912"
          xlink:type="locator"/>
        <link:footnote id="f19d85161-5ecb-4674-8395-636c0929b8b3" xlink:label="f19d85161-5ecb-4674-8395-636c0929b8b3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date and considering the term of the lease to determine the present value of lease payments. We used the incremental borrowing rate of 10.25% on February 28, 2019, for operating leases that commenced prior to that date through December 31, 2021. We used an incremental borrowing rate of 5.65% for the NC lease.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133176912"
          xlink:to="f19d85161-5ecb-4674-8395-636c0929b8b3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c133175712"
          xlink:label="c133175712"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c133175723"
          xlink:label="c133175723"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c133175719"
          xlink:label="c133175719"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c133175711"
          xlink:label="c133175711"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c133175724"
          xlink:label="c133175724"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c133175720"
          xlink:label="c133175720"
          xlink:type="locator"/>
        <link:footnote id="f78b1bd14-f262-4311-b555-318afceeb71a" xlink:label="f78b1bd14-f262-4311-b555-318afceeb71a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Amounts as of December 31, 2023 have been reclassified to conform to current period presentation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175712"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175723"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175719"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175711"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175724"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c133175720"
          xlink:to="f78b1bd14-f262-4311-b555-318afceeb71a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
